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ABSTRACT
Utilization of the Persistent Nature of Brucella in the Development of Live Vaccines.
(August 2005)
Priscilla Christine Hong, B.S., University of San Francisco
Chair of Advisory Committee:  Dr. Thomas A. Ficht
The roles of genes responsible for the survival and persistence of Brucella in the
host and the relationship between these genes and the disease were investigated via
signature-tagged transposon mutagenesis.  As much as 8% of the Brucella genome is
important for survival of this organism in the host.  This is an unusually high number
and may help to explain the chronic or persistent nature of Brucella infections.  Mutants
attenuated in the mouse model were divided into two groups.  The early mutants failed
to establish infection or colonize the host.  The late mutants colonized the host but failed
to maintain infection.  The vaccine potential of two mutants (virB10 and gcvH) that were
unable to sustain infection was compared to that of a vaccine strain, S19.  Survival of
strain S19 in vivo was up to 12 weeks while virB10 and gcvH mutants were cleared from
spleen at 8, and 24 weeks post-inoculation, respectively.  Mice were vaccinated with
individual mutants and then challenged with virulent S2308 at 8, 16, and 24 weeks post-
vaccination.  As a result, protective immunity correlated with persistence of the mutant
strain [gcvH>virB10].
iv
These results suggest that survival is one of several factors that may influence
protective immunity making it difficult to compare strains.  For example, examination of
host immune response revealed a similar pattern of host immune function (TH1 over
TH2) in all mice except those vaccinated with virB10 mutant.  Since gcvH mutant
provided the best immunity, experiments were designed to explore its contribution of
persistence to protection.  In an effort to reduce non-specific activation induced by
prolonged survival of gcvH mutant, protection was monitored after different periods of
vaccination exposure followed with doxycycline treatment.  In these studies, persistence
of gcvH mutant enhanced protection against challenge.  Overall, defined mutations in
genes affecting survival may render mutants as vaccine candidates capable of
stimulating protective immunity equal to or better than fortuitously isolated attenuated
strains.  Future studies should focus on characterization of these and other genes
responsible for the persistence of Brucella to improve the safety and efficacy of live
vaccines.
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1CHAPTER I
INTRODUCTION
Background
Brucella spp.  Brucellae are small, non-motile, anaerobic, non-fermenting, Gram-
negative bacteria.  They are pathogenic for many mammalian species and for humans,
producing chronic infections with persistent or recurrent bacteremia (121), (120).  Six
species are recognized within the genus:  B. abortus, B. melitensis, B. suis, B. ovis, B.
canis, and B. neotomae.  This classification is mainly based on the difference in
pathogenicity and in host preference (33).  Brucella species and their different biotypes
are currently distinguished by differential tests based on sero-typing, phage typing, dye
sensitivity, CO2 requirement, H2S production, and metabolic properties.  B. abortus, B.
melitensis, B. neotomae or B. suis strains may occur as either smooth or rough strains
expressing smooth-lipopolysaccharide (S-LPS) or rough-lipopolysaccharide (R-LPS) as
major surface antigen.  B. ovis and B. canis, on the other hand, are two naturally rough
species, expressing R-LPS as major surface antigen.  They are responsible for ram
epididymitis and canine brucellosis, respectively.  B. canis is occasionally involved in
human brucellosis.  Other strains, hitherto unclassified, have been isolated from marine
mammals. The main pathogenic species worldwide are B. abortus, responsible for
bovine brucellosis; B. melitensis, the main etiological agent of ovine and caprine
_________________________
This dissertation follows the style and format of Infection and Immunity.
2brucellosis; and B. suis responsible for swine brucellosis.  These three Brucella species
usually cause abortion in their natural hosts, resulting in huge economic losses.
B. abortus and B. melitensis, the causative agents of epidemic bovine abortion
and Malta fever respectively, are the most extensively studied Brucella organisms.
These bacteria commonly gain entrance via the conjunctivae, the alimentary tract, the
respiratory route, and broken skin.  At the site of uptake in the skin or mucous
membranes, the organisms are engulfed by phagocytes, multiply and persist within
membrane-bound compartments, and are carried via the lymphatic system to the regional
lymph nodes.  In pregnant animals, brucellae reach the gravid uterus, penetrating the
trophoblasts where they proliferate extensively, resulting in abortion.
Members of the genus Brucella have not been described to harbor plasmids or
produce capsule or exotoxins. Most of them have two chromosomes of 2.1 and 1.5 Mb,
respectively; and both replicons encode essential metabolic and replicative functions and
hence are chromosomes and not plasmids (97).  Although infection may progress
through cycles, i.e. undulant fever, the only demonstrated antigenic variation is the
transition of smooth to rough phenotype (5), (111), (84).
The disease in humans is characterized by a multitude of somatic complaints,
including fever, sweats, anorexia, fatigue, malaise, weight loss, and depression.
Localized complications may involve the cardiovascular, gastrointestinal, genitourinary,
hepatobiliary, osteoarticular, pulmonary and nervous systems.  Without adequate and
prompt antibiotic treatment, some patients develop a “chronic” brucellosis syndrome
with many features of the “chronic fatigue” syndrome (143).
3Brucella species are classified as facultative intracellular pathogens that can
infect non-phagocytic and phagocytic cells.  B. abortus inhibits degranulation and the
oxidative burst in neutrophils (13), (85).  In macrophages, B. abortus survives by
preventing phagolysosomal fusion (18), (41), (65), (107).  Inhibition of phagolysosomal
maturation is also evident in HeLa cells infected with virulent B. abortus S2308 (108).
Initially, both virulent S2308 and attenuated S19 are located transiently in
autophagosomes associated with early endosomal compartments but bypass interactions
with late endocytic compartments.  However, at later times of the infection, the virulent
S2308 is targeted to compartments of ER where massive intracellular multiplication
occurs while the non-pathogenic S19 undergoes degradation after fusion of its
autophagic vacuole with lysosomes.  Some brucellae may be found in autophagosomes
of professional phagocytic cells.  However, the majority of bacteria remain in the
phagosome.  Eventually brucellae are found to reside in phagolysosomes and appear to
be resistant to host killing mechanisms (6).  To cause chronic infection, B. abortus relies
on the intracellular survival within phagocytic cells, yet the mechanisms and virulence
factors responsible for the ability of brucellae to evade antibacterial activities of the host
phagocyte remain to be discovered.
Chronic infection is characterized by continued persistence within host
macrophages.  In the primary host, i.e., ruminants, persistence of brucellae ultimately
leads to acute infection of the pregnant host resulting in abortion of the fetus.  In
secondary hosts such as humans, mice, or even non-pregnant ruminants including males,
chronic infection alone is observed.  Males do not ordinarily suffer from prolonged
4illness, although orchitis may be observed which is most frequently caused by B. ovis
infection in sheep.  Since chronic infection is the key to developing clinical brucellosis,
we have selected a murine model to identify B. abortus genes that are essential for
establishing and maintaining chronic infection.  The murine model has proven to be an
excellent predictor of virulence in the primary host (36) (48), (67).  In this animal model,
we expect the attenuation of Brucella to serve as a predictor of virulence in both bovine
and human hosts.  Understanding the mechanisms of microbial persistence of B. abortus
can also serve as a model system in studying chronic infectious diseases caused by
pathogens that are genetically difficult to manipulate.
Study I
Genes required for chronic persistence of B. abortus in mice.  The first study in this
manuscript described the identification of genes in B. abortus necessary for the
establishment and maintenance of chronic infection in the murine model.  Signature-
tagged mutagenesis (STM), a novel technique developed to circumvent individual and
labor-intensive analysis of mutants for loss-of-function phenotype or attenuation of
virulence was employed (66).  This negative selection method allows a collective
screening of pools of mutants simultaneously.  The technique is based on the fact that
DNA tags inserted within the miniTn5 system can be identified by PCR and colony blot
or dot blot hybridization.  The absence of tags in the recovered pools (output) compared
to those present in the inoculum (input) pool is an indication of attenuation in virulence
of the mutants in the host.  Signature-tagged mutagenesis can therefore be used to
5identify new bacterial virulence genes whose functions are required for the successful
colonization of certain habitats.
To examine the ability of B. abortus to establish infection and persist in the host,
a bank of STM mutants was constructed in which each mutant carried a unique tag as a
result of a single random transposon insertion in the genomic chromosome.  Observed
negative phenotypes of a few single insertional mutants could be attributed to the
inactivation of genes by unique tagged transposons.  Having demonstrated the validity of
the insertional mutagenesis, the mutant bank was screened for mutants that were
attenuated in the murine model of infection.  The murine model is smaller and more
affordable in cost and in housing than the large animal model such as the cow, which is
the primary host of B. abortus.  More importantly, the murine model has been used
extensively for detecting differences in virulence among brucellae (8), (98), (99), (100),
(133).  Studies have shown that vaccine strain S19 that persists longer than many
attenuated strains is more rapidly cleared from mouse spleens than virulent S2308 after
an infection (48), (51), (132).  The ability of Brucella to persist within the mouse is
directly attributable to intracellular survival within macrophages (1), (53), (54), (129).
The STM method provides a qualitative identification of candidates that are
potentially attenuated for intracellular survival in the host.  Cross feeding of mutants
may occur in a complex pool of mutants, i.e., a negative phenotype in one mutant may
be complemented by other mutants.  Alternatively, some mutants may survive poorly in
competition with 49 other mutants in the infectious dose. To address these potential
problems, the mutants identified in the original STM screen were confirmed by
6performing a mixed infection (1-to-1) of B. abortus S2308 (parental strain) with
individual candidate, attenuated mutants.  However, mutants that were complemented in
trans in the presence of the other mutants might be missed using this assay.  To exclude
the possibility that the attenuating phenotypes of these candidate mutants are due to
growth defects, individual candidate mutants along with S2308 were competitively
tested for the ability to grow in vitro tryptic soy broth.
The ability of various strains of B. abortus to survive in macrophages in vitro has
been shown to correlate with their virulence in vivo (1), (26), (34), (46).  During the
course of infection in mice, the initial growth of Brucella in the spleen is temporarily
halted by the onset of heightened macrophage bactericidal activity (24), (87), (93).
Macrophage activation occurs very early during Brucella infection, and persists as late
as 60 days post-infection, well into the latent phase of the infection (8), (14).  Therefore,
to persist in a host Brucella must be able to survive and replicate within the environment
of the macrophage.  In vitro studies involving cytokine activation of macrophages have
shown that IFN-gamma has the most consistent and dramatic enhancing effect on the
ability of murine macrophages to control the growth of Brucella (72), (71), (74).
However, the efficacy of IFN-gamma activation has no effect on the clearance of
bacteria.  Therefore, the ability of Brucella to establish its niche in the host macrophage
was examined by evaluating individual STM attenuated mutants for survival in the
macrophage-like cell line J774A.1.
Although housekeeping functions were of little interest in identifying novel
virulence mechanisms, they would serve as targets for development of improved vaccine
7strains or for therapeutic treatment.  Brucella spp. are able to grow in what is suspected
to be a nutrient-poor environment within macrophage vacuoles, suggesting that they
have the ability to synthesize all the metabolites necessary for survival.  Thus, a
mutation in any gene encoding key enzymes in metabolic pathways that cannot be
acquired from the host intracellular environment, results in reduced survival in
macrophages.  For example, certain Brucella auxotrophs including amino acid
biosynthesis (carAB, leuA), and glutamine metabolism (glnD) are attenuated in
macrophages (50), (53).  Purine auxotrophs of B. melitensis and of several pathogens are
also attenuated in macrophages and in mice (34), (42).  Thus, to elucidate the metabolic
pathways required by Brucella to survive intracellularly in host macrophages, the
attenuated STM mutants were screened for auxotrophs.  The screening for auxotrophs
helps to identify nutrient compounds that may not be readily available to Brucella living
inside a phagosome.  In addition, when the attenuating phenotype was not due to
metabolic defects, the screen provides a mean to demonstrate that the observed
attenuation was caused by the inactivation of novel virulence factors that are necessary
for the survival of Brucella within the macrophage.
Study II
B. abortus mutants defective in persistence in mice confer protection against
virulent challenge.  The second study described the comparison of B. abortus STM
mutants defective in persistence in the mouse model for their ability to stimulate
protective immunity.  In contrast to mutants defective for resistance to stress and other
8environmental hazards that poorly colonize the host, mutants defective for maintaining
chronic infection colonized the host normally, but failed to persist or thrive.  Mutants
with inactivated genes that were required for chronic infection became ideal for live
vaccine development.  To be effective, live attenuated vaccines against brucellosis must
persist long enough to elicit protective immunity, but should be cleared as quickly as
possible to avoid unnecessary side effects. In order to determine whether greater
persistence correlates with greater protection, the ability of selected mutants to protect
vaccinated mice against a challenge infection of wild type B. abortus was examined at
different time points following vaccination.  Protective immunity against Brucella
infection has been studied in several mouse models (BALB/c, CD-1, CBA, C57Bl/10
mouse strains) (16), (25), (28), (70), (138), (152), (153).  The criterion used for
measuring protection in immunized mice is the reduction, at a specified time, after a
virulent challenge, of the number of colony-form units (CFU) of Brucella recoverable
from the spleen or liver or both (110).  The level of protective immunity was also
analyzed by spleen weights from groups of mice vaccinated with different mutants, since
splenomegaly is indicative of severity of the infection.  T cells play a major role in the
acquired specific resistance to intracellular bacteria determining the resolution of
infection.  Thus, cytokine profiles induced by different mutants were analyzed and
compared to that induced by the wild type S2308.  The IgG2a and IgG1 patterns analyzed
from each group of vaccinated animals was another measure of the cell-mediated
immunity.  In addition, the adaptive or acquired immunity were characterized by
lymphocyte proliferative response and antibody titers.  The comparison of T cell-
9mediated responses between different mutant strains helps to identify predictive
correlates of adaptive immunity and to establish whether optimal immunity is a function
of the survival and/or the intracellular trafficking and processing of the organism.
Study III
Isolation of gcvH in B. abortus.  The last study described the isolation of the gcvH, an
important locus shown to be required for persistence within the host.  The ability of B.
abortus to successfully establish and maintain chronic infection can be attributed to the
long-term survival and growth of Brucella within the host macrophage.  In the hostile
conditions encountered within the macrophage, brucellae elicit changes in gene
expression resulting in the induction of stress response proteins (89), (80), (118).  Stress
response proteins such as DnaK, GroE, Lon, and Clp, may serve to aid in adaptation to
the harsh environment of phagocytic cells (44), (88), (118), (142).  These gene products
may be involved in removing damaged or misfolded proteins before they can accumulate
to toxic levels.  Others such as antioxidants, SodC and KatE, may play a role in the
intracellular oxidative defense mechanisms and hence protecting brucellae from the
oxidative burst in the host macrophage (141), (77), (78).  Interestingly, previous studies
have shown that the intracellular survival of B. abortus can be reduced by the disruption
of the cydBA operon whose products are involved in the terminal step of the electron
transport chain (46).  The function of this protein appears to be essential to prevent
oxidative stress under the conditions encountered in the host.
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The intracellular niche of the phagocytic cell is the prominent feature shared by
another facultative intracellular pathogen, Mycobacterium tuberculosis.  Infection with
M. tuberculosis can result in the active tuberculosis and/or the latent infection.  The
latency of the disease in humans and experimental animals is due to the persistence of
the tubercle bacillus in the host (105).  Wayne et al. (150) has reported that M .
tuberculosis is capable of adapting to prolonged periods of dormancy in tissues and that
dormant bacilli are responsible for the latency of the disease itself.  The process of
shiftdown of M. tuberculosis from active replication to dormancy, but not death, has
been described through the in vitro system as (a) changes in tolerance to anaerobiosis,
(b) production of a unique antigen and (c) a ten-fold increase in glycine dehydrogenase
production (147), (149).  The unique antigen, URB, is present only in dormant bacilli,
and not in well-aerated replicating cultures.  The enzyme glycine dehydrogenase
catalyzes the reductive amination of glyoxylate, concomitantly oxidizing NADH to
NAD.  Under conditions of reduced oxygen availability found in inflammatory and
necrotic tissues, glycine dehydrogenase can serve to regenerate NAD from its reduced
form, thus providing energy for M. tuberculosis to shift down to a stable, non-replicating
form that merely tolerates anaerobiosis.  Providing NAD and thus ATP may be
necessary to support the completion of a final cycle of DNA synthesis before the
shutdown of replication.
Although the outcomes of the two diseases are different, persistence of bacteria
in the host is the hallmark of chronic infection caused by Brucella and of the latent
infection caused by Mycobacteria.  In the latency of tuberculosis, the level of glycine
11
dehydrogenase increases in dormant tubercle bacilli, yet the gcvP gene encoding the
enzyme has not yet identified in M. tuberculosis.  In B. abortus the gcvH mutant shows a
defect in the ability to persist in the host, indicating that Brucella and Mycobacteria may
depend on a similar metabolic pathway for chronic persisence in the host.  The next step
in characterizing the gcvH locus was to restore or rescue the attenuated phenotype of the
gcvH mutant.  First, all three genes of the gcv operon must be fully expressed in order to
have a functional glycine cleavage system.  The introduction of wild-type copy of gcvH
and gcvP into the mutant was accomplished via the use of a low-copy, broad host range
plasmid.  Then the complemented mutant strains were evaluated for their ability to
survive in mice as well as in the macrophage.  The outcome of the in vivo and in vitro
survival of the complemented mutant strains would be invaluable for future studies on
the regulation and expression of the gcv operon in B. abortus.
12
CHAPTER II
IDENTIFICATION OF GENES REQUIRED FOR CHRONIC PERSISTENCE
OF BRUCELLA ABORTUS IN MICE *
Overview
The genetic basis for chronic persistence of Brucella abortus in lymphoid organs
of mice, cows, and humans is currently unknown.  We identified B. abortus genes
involved in chronic infection, by assessing the ability of 178 signature-tagged mutants to
establish and maintain persistent infection in mice.  Each mutant was screened for its
ability to colonize the spleens of mice at 2 and 8 weeks after inoculation.  Comparison of
the results from both time points identified two groups of mutants attenuated for chronic
infection in mice.  The first group was not recovered at either 2 or 8 weeks post-infection
and was therefore defective in establishing infection.  Mutants in this group carried
transposon insertions in genes involved in lipopolysaccharide biosynthesis (wbkA), in
aromatic amino acid biosynthesis, and in type IV secretion (virB1 and virB10).  The
second group, which was recovered at wild-type levels 2 weeks post-infection but not
8 weeks post-infection, was able to establish infection but was unable to maintain
chronic infection.  One mutant in this group carried a transposon insertion in a gene with
homology to gcvB of Mycobacterium tuberculosis, encoding glycine dehydrogenase, an
_________________________
*Reprinted with permission from “Identification of Genes Required for Chronic
Persistence of Brucella abortus in Mice” by Priscilla Christine Hong, Renee M. Tsolis,
and Thomas A. Ficht, 2000.  Infection and Immunity, Volume 68, p. 4102-4107,
Copyright © 2000 by the American Society of Microbiology.
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enzyme whose activity is increased during the state of nonreplicating persistence.  These
results suggest that some mechanisms for long-term persistence may be shared among
chronic intracellular pathogens.  Furthermore, identification of two groups of genes,
those required for initiating infection and those required only for long-term persistence,
suggests that B. abortus uses distinct sets of virulence determinants to establish and
maintain chronic infection in mice.
Introduction
Bacteria causing chronic infections, such as Mycobacterium tuberculosis,
Chlamydia trachomatis, and Brucella abortus are able to evade the host's immune
system throughout the infection by colonizing an intracellular niche.  This lifestyle may
require adaptations other than the brief survival in phagocytic cells observed for well-
characterized intracellular pathogens such as Salmonella serotypes which cause an acute
infection.  While M. tuberculosis and C. trachomatis are difficult to manipulate
genetically, the genetic manipulation of the Brucella genome can be performed
routinely, using tools such as plasmid vectors and systems for Tn5 mutagenesis (75),
(83), (86).  Thus, identification of the genes required by B. abortus to cause infection
may reveal virulence mechanisms of chronic disease caused by other intracellular
pathogens.  A recent improvement in Tn5 mutagenesis, known as signature-tagged
transposon mutagenesis (STM), has been developed for the in vivo selection of Tn5
mutants that are defective in colonization (66).  This method uses experimentally
infected animals to identify mutants that are attenuated in vivo from a large, mixed pool
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of mutants (126).  Since Tn5 can be used in B. abortus, STM can be used to identify
genes that are necessary for chronic intracellular infection.
Brucellosis is endemic in Mediterranean countries and Central and South
America and is manifested as an undulant fever in humans that, if untreated, can develop
into a chronic infection with symptoms persisting for several months (154).  Chronic
infections may result in infection of secondary tissues, including heart and brain, if the
infection is left untreated.  Symptoms may also recur years after the original infection.
B. abortus infection is acquired by humans through contact with infected livestock and
consumption of unpasteurized dairy products.  Bacteria cause a systemic infection and
localize preferentially to organs that are rich in elements of the reticuloendothelial
system, such as liver, spleen, and lymph nodes, where they survive and multiply within
host macrophages.  B. abortus has been found to inhibit the bactericidal functions of
phagocytes, including phagolysosomal fusion, neutrophil degranulation, and the
oxidative burst (8); however, as with other intracellular pathogens which cause chronic
infection, the genetic basis for the interaction of Brucella with phagocytic cells is still
poorly understood.  B. abortus virulence is conveniently studied in a mouse model that
mimics the chronic infection observed in humans.  Here bacteria are found
intracellularly, within macrophages of infected organs (96).  Experimental infection of
BALB/c mice has shown that the infection has two phases: during the first 2 weeks,
bacteria multiply rapidly.  In the second phase, bacterial numbers stabilize over the next
5 to 6 weeks and then decrease slowly.  Bacteria have been recovered from spleens of
infected mice as late as 24 weeks post-infection (98), (112).  The different phases of
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B. abortus infection in mice raise the question whether this pathogen uses different sets
of virulence genes during the early and late stages of this disease.
To address this question, we have performed a random screen of the genome of
B. abortus to identify genes required for infection at an early (2 weeks post-infection)
and a late (8 weeks post-infection) time point postinoculation.  Comparative analysis of
these results provided new insight into the genetic basis for chronic intracellular
infection and B. abortus pathogenesis.  Furthermore, our results suggest that a better
understanding of the mechanisms by which B. abortus is able to cause chronic
intracellular infection may ultimately reveal strategies that are shared by other, less
tractable pathogens.
Materials and Methods
Construction of mutants and growth conditions.  B. abortus strain 2308 (obtained
from B. L. Deyoe, National Animal Disease Center, Ames, Iowa) was used as a host for
STM. A bank comprising 240 signature-tagged B. abortus mutants (ST mutants) was
constructed using a pool containing 10,000 uniquely tagged mini-Tn5Km2 derivatives
carried on suicide plasmids, which was obtained from David Holden (66).  The
transposons were introduced into B. abortus S2308 by electroporation and selected on
tryptic soy agar (TSA; Difco) containing 100 mg of kanamycin (Km) per liter (1).
Approximately 20 mutants were taken from each of 10 individual electroporations in
order to minimize the isolation of siblings.  Mutants resistant to ampicillin were
eliminated from the pool, since they carry the suicide vector inserted into the
16
chromosome.  For infection of mice, B. abortus strains were grown on potato infusion
agar (PIA; Difco) for 48 h and resuspended at the appropriate concentration in
phosphate-buffered saline (PBS) (3).  For determination of auxotrophy, the chemically
defined solid medium formulated by Gerhardt was used, which contains glycerol,
glutamate, lactate, thiamine, nicotinic acid,biotin, calcium pantothenate, and inorganic
salts (58).  This basal medium was supplemented with 10 groups of amino acids to
perform auxanography for attenuated mutants.  All work with live B. abortus was
performed in a biosafety level 3 containment facility following Centers for Disease
Control-National Institutes of Health guidelines.
Infection of mice.  For the mutant screen, pools of 46 mutants were used to infect
groups of six 6- to 8-week-old BALB/c mice intraperitoneally (i.p.) at a total dose of
approximately 106 CFU.  Groups of three mice were sacrificed at 2 and at 8 weeks post-
infection, and bacteria were recovered from the spleens.  Spleens were homogenized in
3 ml of PBS, and serial 10-fold dilutions were plated on TSA-Km.
Signature-tagged screen and hybridization analysis.  Bacteria recovered from murine
spleens at 2 and 8 weeks post-infection were pooled to obtain one output pool from each
mouse.  Total chromosomal DNA was prepared from each output pool to serve as a
template for generating probes containing labeled tags, as described before (66).
Labeled tags used as probes were prepared by incorporation of [-32P]dATP during PCR
amplification of tags from total chromosomal DNA.  Blots containing chromosomal
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DNA from individual mutants in each pool were prepared by transferring pools of
B. abortus ST mutants from 96-well plates onto nylon membranes laid on top of TSA
plates with a 48-prong replicator.  Hybridization and washes were carried out under
stringent conditions (7).  To identify potentially attenuated mutants, hybridization
signals on a blot probed with labeled tags prepared from the input pool (inoculum) were
compared with three identical blots hybridized with tags prepared from the output pools
recovered from the three mouse spleens at each time point.  Mutants giving a
hybridization signal with the input pool but no signal in the output pool of at least two
mice were selected for further study.  To confirm that each mutant carried a single
insertion of mini-Tn5 in the chromosome, mutants were analyzed by Southern blot (7).
Chromosomal DNA was prepared (7) and digested with EcoRI, which cuts once within
the transposon, outside the kanamycin resistance gene.  After agarose gel electrophoresis
and transfer to nylon membranes, chromosomal DNA was analyzed by hybridization
with a probe containing a 1.3-kb fragment of the Tn903 kanamycin resistance gene from
plasmid pUC4KSAC (Pharmacia).  Mutants whose chromosomal DNA gave a
hybridization signal with a single band on the Southern blot were determined to have
only one copy of the transposon inserted into the chromosome.
Competitive infection assay.  For competitive infection experiments, groups of four
mice were inoculated i.p. with an approximately 1:1 mixture of mutant and wild-type
B. abortus, at a total dose of approximately 105 CFU.  Mice were sacrificed at 2 or
8 weeks post-infection, and bacteria were recovered from infected spleens.  The CFU of
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mutant and wild-type B. abortus recovered from infected spleens were enumerated by
serial dilution in PBS and plating in parallel on TSA and TSA-Km.  Numbers of wild-
type and mutant bacteria were calculated by subtracting the CFU recovered on TSA-Km,
on which only the Tn5 mutants are able to grow, from the CFU recovered on TSA
plates, representing the total number of bacteria recovered.  Data were normalized by
dividing the output ratio of (CFU [wild type]/CFU [mutant]) by the input ratio of (CFU
[wild type]/CFU [mutant]).  All data were then converted logarithmically for statistical
analysis.  A Student's t test was used to determine whether the wild-type/mutant ratio
recovered from infected spleens was significantly different from the wild-type/mutant
ratio present in the challenge inoculum.
Cloning and sequence analysis.  Transposon-flanking DNA was cloned by inverse
PCR as described previously (9) using RsaI for digestion of chromosomal DNA and the
primer pair SIGN-10 (5'-GCCGAACTTGTGTATAAGAGTCAG-3') and SIGN-11 (5'-
AAAGGTAGCGTTGCCAATG-3').  The PCR products were ligated into cloning vector
pCR II (Invitrogen), and plasmid DNA for sequencing was isolated from Escherichia
coli strain DH5 (62) using ion-exchange columns from Qiagen.  In addition, larger DNA
fragments flanking the transposon insertions in several of the mutants were cloned by
ligating PstI- or EcoRI-restricted genomic DNA into cloning vector pBluescript SK+
restricted with the appropriate enzyme and selection for the kanamycin resistance marker
of mini-Tn5Km2 (39).  Nucleotide sequences were analyzed using the MacVector
6.5 software package (Oxford Molecular Group).  Sequence homology was determined
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using the BLAST2 search algorithm at the National Center for Biotechnology
Information (NCBI) (4).
Results
Generation of signature-tagged mutants of B. abortus.  B. abortus 2308 was
mutagenized with a pool of signature-tagged mini-Tn5Km2 derivatives carried on
plasmid pUT by electroporation, and mutants were selected on TSA-Km.  These mutants
were screened for susceptibility to ampicillin to eliminate strains (fewer than 2% of
mutants) carrying cointegrates of the suicide vector pUT inserted in the chromosome.
To confirm that mutants obtained from the same electroporation are not siblings but arise
from independent transposition events, Southern hybridization was performed using the
1.3-kb EcoRI fragment of pUC4KSAC, which contains the Tn903 Kmr gene (39).
Using this probe, the hybridization profiles of EcoRI-digested chromosomal DNA from
10 randomly chosen mutants from a single electroporation were compared.  Since EcoRI
cuts only once within miniTn5Km2, a mutant with a single transposon insertion should
have only one band hybridizing with the probe.  All of the mutants examined had a
single band of unique size hybridizing with the probe, indicating that each mutant
contained a single, unique insertion of the transposon (data not shown).
Signature-tagged screen of B. abortus mutants in mice.  To identify mutants defective
in establishing chronic infection, we used the BALB/c mouse model of chronic
brucellosis.  Mice infected i.p. with B. abortus have been shown to harbor bacteria in the
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spleen for up to 24 weeks post-infection (8), (14).  The persistence of B. abortus in mice
is similar to chronic infection observed in other host species, including humans.  It has
not been shown whether attenuated B. abortus mutants exhibit competitive infection
defects in mice when coinoculated with a virulent strain.  We therefore performed a
preliminary competitive infection experiment using B. abortus 2308 and CA180, a Tn5
mutant defective in the synthesis of the O antigen of lipopolysaccharide (LPS), which
was characterized previously (1).  Three mice were infected i.p. with a mixture
containing 6.4 Å~ 104 CFU of B. abortus 2308 and 4.1 Å~ 104 CFU of CA180.  At
1 week postinfection, no mutant B. abortus could be recovered from the spleens of any
infected mouse, while the number of wild-type B. abortus ranged from 6 Å~ 103 to
2 Å~ 106 CFU/spleen.  This result showed that a mutant with a defect in a known
B. abortus virulence factor, LPS, exhibits a competitive infection defect in the BALB/c
mouse model of brucellosis.  Furthermore, it suggested that STM, which utilizes
competitive infection as the basis for screening pools of mutants, could be used to screen
for mutants defective in chronic infection.
For the screen in mice, pools of 46 mutants were grown individually in tryptic
soy broth (TSB) in 96-well plates for 48 h and then stamped with a 48-prong replicator
onto PIA plates and grown for 48 h. Bacteria were resuspended from PIA plates, and the
concentration was adjusted to approximately 107 CFU/ml with PBS.  Of this suspension,
0.1 ml was injected i.p. into each of six BALB/c mice.  In the pooled inoculum, the dose
of each individual mutant was therefore approximately 104 CFU.  At 2 and 8 weeks post-
infection, groups of three mice were sacrificed.  At necropsy, the only sign of disease
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evident was the enlargement of the spleen.  To recover bacteria, spleens were
homogenized in PBS, and serial 10-fold dilutions were plated on TSA-Km.  After
incubation for 4 days, bacteria were resuspended from plates containing between
1,000 and 5,000 colonies, and chromosomal DNA was prepared from the recovered pool
of mutants.  Probes of input and output pools were generated by PCR amplification of
tags from chromosomal DNA of pooled STM mutants as described before (66) and used
for hybridization with dot blots containing individual mutants in the corresponding pool.
For each time point, a fresh input pool probe was prepared and a blot was hybridized for
comparison with the output pools recovered from the mice.  We found that 39 mutants
failed to give a reproducible hybridization signal when the input pool probe was
prepared more than once from a chromosomal DNA preparation.  These mutants were
eliminated from the screen.  Thus, a total of 178 mutants with consistently hybridizing
tags were screened.
Mutants which gave weak or no hybridization signals on output pool blots from
at least two of the three mice at each time point were identified as putatively attenuated
by comparison with input pool blots (Fig. 1).  At 2 weeks post-infection, 28 mutants
exhibited a reduction in the hybridization signal, suggesting reduced recovery from the
mouse spleens.  Of these 28 mutants, 11 exhibited a reduced hybridization signal in
output pools recovered at 8 weeks post-infection.
In addition to the 11 mutants reduced in colonization at both 2 and 8 weeks, we
identified 16 mutants that were only defective for colonization at 8 weeks.  While
mutants identified from both the 2- and 8-week output pools may be unable to establish
22
Fig. 1.  Dot blots.  Colony blots showing hybridization of B. abortus ST mutants with
probes containing tags amplified from the input pool and from output pools recovered
from spleens of three mice at 8 weeks postinfection.  At the upper left and lower right
corner of each blot is the parent stain, B. abortus 2308.  Arrows indicate mutants
(BA142, BA152, BA159, and BA184 [left to right]) which gave weak signals in the
output pools of at least two of the three mice inoculated and whose competitive infection
defect was confirmed subsequently.  Open squares indicate mutants that gave
inconsistent hybridization results and were therefore eliminated from the screen.
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infection, those identified only from the 8-week output pools may be defective in
sustaining chronic infection.  The 17 mutants identified only from the 2-week output
pools may represent mutants, which are slow to colonize the spleen, but are still able to
persist.  However, infection defects in these mutants were not characterized further,
since these mutants were able to sustain chronic infection.  Thus, two groups of mutants,
those identified at both 2 and 8 weeks and those identified only at 8 weeks, were
considered putatively attenuated for chronic infection and were chosen for further study
(Table 1).
Competitive infection of mice with mutants identified by STM.  Following our
identification of mutants putatively attenuated for chronic infection, we performed a
quantitative assay to confirm their colonization defect.  To this end, each of the
27 mutants identified by the STM screen was inoculated i.p. at a 1:1 ratio with wild-type
B. abortus at a total dose of approximately 105 CFU to groups of four mice (Table 1).
As a control, mutant BA53, which was recovered at both 2 and 8 weeks post-infection
from mice, was selected at random from the STM pool as a negative control and
administered to mice in a competitive infection experiment as described above.  During
mixed-infection experiments, 15 mutants identified in the STM screen were found to
have a significant defect in persistence in mouse spleens.  One of these mutants, BA11,
had a significant colonization defect only at 2 weeks and therefore was not characterized
further.  Thus, for 14 of 27 mutants identified in the preliminary STM screen, the
putative chronic infection defect could be confirmed by a significant reduction in
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Table 1:  Confirmation of competitive defects of STM mutants by competitive infection
of mice with B. abortus S2308
Mutant competitive indexa
in vivo
___________________
  2   weeks         8 weeks
competitive
index
in vitro
Mutant competitive
index
_in vivo__
   8 weeks
BA11 2.29 1.86 BA18 0.064
BA41 4.74* >29512*** 0.97 BA27 2.24
BA73 3.36 147.9* 2.74 BA31 3.63*
BA87 1.08 10.47** 0.79 BA38 7.76*
BA100 20.89*** >758.6*** 4.70 BA63 1.86*
BA102 1.47 93.3*** 1.80 BA70 3.39
BA109 0.92 3.21 BA99 1.02
BA114 133.07** >1047.1*** 0.91 BA105 2.00
BA157 0.74 1.58 BA119 6.31
BA159 1.50 23.44* 2.20 BA116 2.51
BA184 1306.8*** >2168.2*** 0.57 BA122 95.50*
BA130 3.02
BA138 3.72
BA140 1.20
BA142 70.79***
BA152 72.44***
a competitive index was calculated as
(CFUS2308/CFUmutant)recovered/(CFUS2308/CFUmutant)inoculated.
Significance of differences between competitive indices of STM  mutants and
a control, non-attenuated mutant were compared using the Student's t test.
*, p<0.05; **, p<0.01, ***, p<0.005.
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colonization during competitive-infection experiments.
Mutants which did not have significant colonization defects in the competitive-
infection assay either may have been false-positives in the STM screen or may only
display competitive colonization defects when inoculated at a wild type-to-mutant ratio
of greater than 1.  However, these possibilities were not investigated further.  Mutants
with significant colonization defects during mixed infections fell into two groups:  those
reduced in colonization at both 2 and 8 weeks, and those reduced at only 8 weeks (Fig.
2).  Subsequent mouse infection experiments showed that mutants with competitive
colonization defects are also attenuated when administered alone to mice (data not
shown).  To determine whether colonization of the spleen was reduced due to a general
growth defect, mutants displaying significant defects at both 2 and 8 weeks post-
inoculation were assayed for in vitro growth defects by inoculating TSB with a mixture
of wild-type and ST mutant strains (Table 1).  With the exception of BA100, which was
outgrown almost fivefold by the parent strain, none of the mutants displayed a strong
growth deficiency in laboratory medium.
Identification of inactivated genes.  Genes inactivated by mini-Tn5Km2 insertions
were identified by cloning transposon-flanking DNA, sequence determination, and
comparison with the GenBank database using the BLAST2 search program at NCBI.
Transposon-flanking DNA was cloned from eight mutants.
Mutants with defects in establishing chronic infection included BA184, which
carried a transposon insertion in a B. abortus homologue of Brucella melitensis wbkA,
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Fig. 2.  Attenuated mutants.  Mutants with statistically significant colonization defects,
as confirmed by individual competitive infections and statistical analysis.  Homologues
of disrupted genes are given in parentheses.  nh, no homology.
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encoding a mannosyltransferase that functions in the biosynthesis of O antigen (61).
LPS biosynthesis is required for virulence in Brucella species, and it has recently been
shown that strains of B. abortus and B. melitensis carrying defined mutations in genes
required for LPS biosynthesis are unable to establish infection in mice (1), (61), (95).
Identification of this known virulence factor thus validated the STM screen.
Two additional mutants with defects in establishing persistent infection, BA41
and BA114, carried transposon insertions in homologues(virB1 and virB10, respectively)
of the Brucella suis virB locus (103).  B. suis mutants carrying disruptions at this locus
show a reduced ability to multiply in vitro within macrophages and HeLa cells.  Our data
suggest that this locus is required for establishing chronic infection in organs of the
mouse.
We could obtain no clone from DNA flanking the transposon insertion of the
fourth mutant (BA100) defective in establishing chronic infection.  However, BA100
was unable to grow on Brucella minimal medium unless supplemented with a
combination of aromatic amino acids.  These auxanography data indicated that this
mutant was defective in an early step of the aromatic amino acid biosynthesis pathway.
Sequences obtained from the transposon insertion site in three mutants defective
in sustaining chronic infection showed homology to metabolic genes.  BA159 was
interrupted at the gluP locus, encoding a putative transporter for glucose and galactose
(49).  Mutant BA152 carried a transposon insertion in a homologue of Rhizobium etli
gltD, encoding the small subunit of glutamate synthase (21).  The identification of these
two mutants in the STM screen suggests that glucose, galactose, or glutamate may serve
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as carbon and/or nitrogen sources during growth of B. abortus in the host.  BA102
carried an insertion in a putative glycine dehydrogenase or glycine cleavage system.
Since BA102 did not have a competitive growth defect in TSA and was able to grow on
minimal medium without glycine, the virulence defect of BA102 is likely not due to
auxotrophy.  Interestingly, the activity of glycine dehydrogenase has been shown to
increase 10-fold upon entry of M. tuberculosis into a state of nonreplicating persistence
(148), (150).  Since B. abortus, like M. tuberculosis, is able to persist chronically in
infected hosts, glycine dehydrogenase may play a similar role in the entry of these
pathogens into a latent state in the host.
Finally, DNA flanking two insertions in mutants defective for maintaining
chronic infection showed either no homology to genes in the database (BA73) or
homology to an open reading frame of unknown function (BA87) (Table 2).
Discussion
The goal of the STM screen was to identify and compare B. abortus genes
required for establishment and maintenance of chronic persistence in the mouse.  Since
fewer than 200 genes have been sequenced in Brucella species, we reasoned that
screening a small number of mutants would be sufficient to identify new B. abortus
genes required for chronic infection. The STM screen identified 27 mutants putatively
attenuated for chronic infection.  A statistically significant competitive-infection defect
could be detected in 14 of these mutants.  Thus, statistically significant evidence for
attenuation was obtained for 8% (14 of 178) of the mutants screened.  Assuming that our
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Table 2:  Characterization of B. abortus genes identified by STM
Mutant Closest homolog
(organism)
GenBank Accession
Number (reference)
inferred function
BA41 virB1 (Brucella suis) AF141604 Type IV secretion
BA114 virB10 (Brucella suis) AF141604 Type IV secretion
BA184 wbkA (Brucella melitensis) AF047478 O-antigen
biosynthesis
BA159 gluP (Brucella abortus) U43785 uptake of glucose
and galactose
BA102 P-protein (Synechocystis
spp.)
gcvB (M. tuberculosis)
D90914
Q50601
glycine
dehydrogenase
BA152 gltD (Rhizobium etli) AF107264 glutamate synthase
BA87 HP1225 (Helicobacter
pylori)
AE000628 conserved inner
membrane protein
BA73 no homology ?
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mutagenesis was random and that the coding density of the 3,200-kb B. abortus genome
is similar to that of the E. coli genome, our data suggest that an estimated 257 genes may
be required for establishing and maintaining chronic persistence in mice after i.p.
infection.  In contrast, i.p. infection of mice with an STM bank of Salmonella
typhimurium revealed that only 3% of its 4,400-kb genome, or an estimated 153 genes, is
required for the acute infection caused by this intracellular pathogen (66). The greater
number of virulence genes required for chronic infection versus acute disease may
reflect the requirement for additional adaptations to ensure long-term persistence, such
as those which prevent clearance of B. abortus by the host immune system.
The working hypothesis of this study was that different sets of genes may be
required for the initial steps or the establishment of chronic infection, which is
characterized by rapid bacterial growth, than for maintenance of chronic infection, in
which little or no growth is observed (8), (14).  Indeed, the 14 attenuated mutants
identified in this study fell into two classes (Fig. 2).  Four mutants were unable to
establish infection by either 2 or 8 weeks post-infection.  In contrast, the remaining
10 mutants were able to establish infection at 2 weeks post-infection but displayed a
defect in chronic persistence at 8 weeks post-infection.  The first class included mutants
with transposon insertions in genes required for O-antigen biosynthesis (BA184), type
IV secretion (BA41 and BA114), and biosynthesis of aromatic amino acids (BA100).
The genes inactivated in these mutants are predicted to play a role early during infection.
For example, BA184, a wbkA  mutant, was the most highly attenuated and was
outcompeted by the wild type by 1,000-fold at 2 weeks postinfection, suggesting that it
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was eliminated early in the infection process.  Since rough mutants are sensitive to the
bactericidal action of complement, it is possible that BA184 is cleared by complement-
mediated lysis and may reach the spleen only in small numbers (1), (30), (43).  The
transposon insertion in BA100 rendered this mutant defective in the biosynthesis of
aromatic amino acids, as determined by auxanography.  This biosynthesis pathway is
also required for the biosynthesis of 2,3-dihydroxybenzoic acid, the only siderophore
known to be produced by B. abortus (90).  However, since this siderophore has been
shown to be dispensable for growth in mice (11), it is more likely that attenuation of this
mutant is the result of its inability to acquire aromatic amino acids in the host.
Salmonella aro mutants are unable to survive and replicate within macrophages and are
attenuated for virulence (68).  Thus, some of the virulence genes required in an early
phase during chronic B. abortus infection may be similar to those used by intracellular
pathogens, such as S. enterica serovar Typhimurium, which cause an acute infection.
Two mutants (BA114 and BA41) defective for initiation of chronic infection
carried insertions in a putative type IV secretion system of B. abortus, encoded by the
virB genes (103).  Mutant BA114 (virB10) displayed a greater competitive colonization
defect in murine spleens at 2 weeks post-infection than BA41 (virB1) (Table 1).  A
similar effect has been described for the homologues of the B. abortus virB10 and virB1
genes present in the genome of the plant pathogen Agrobacterium tumefaciens.
Inactivation of virB1 in A. tumefaciens causes a lower degree of attenuation than a
mutation in virB10 (12).  Mutations in the virB locus render B. suis unable to multiply in
HeLa cells or macrophage cell lines in vitro (103).  These data, together with our
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findings that B. abortus virB1 and virB10 mutants are unable to persist in mouse spleens
after i.p. inoculation, suggest that attenuation in the animal model is due to an inability
of these strains to grow intracellularly.
The second class of mutants, which were unable to maintain chronic infection,
included strains defective in production of glutamate synthase (BA152), glycine
cleavage (BA102), nutrient uptake (BA159), and several unknown functions (BA31,
BA38, BA73, BA87, BA63, BA122, and BA142).  While the inactivated genes in these
mutants were not required for initiation of infection, they were required for chronic
persistence.  Mutant BA102 carried a transposon insertion in a gene with homology to
gcvB, encoding glycine dehydrogenase, from M. tuberculosis.  The activity of this
enzyme has been found to increase 10-fold upon entry of M. tuberculosis into a state of
nonreplicating persistence in vitro (150).  The finding that glycine dehydrogenase is
required for persistence of B. abortus in the mouse spleen suggests that M. tuberculosis
and B. abortus may depend on similar metabolic pathways for chronic persistence in the
host.  This result underscores the potential for research on host pathogen interactions of
B. abortus to elucidate mechanisms of intracellular persistence which are shared by other
chronic intracellular pathogens.
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CHAPTER III
BRUCELLA ABORTUS MUTANTS DEFECTIVE FOR MAINTAINING
CHRONIC INFECTION CONFER PROTECTION IN BALB/C MICE
Overview
Protection against brucellosis requires a TH1 response including the enhanced
activation of professional phagocytes.  Immunity to Brucella infection relies on the use
of fortuitously attenuated vaccine strains.  Research in the development of live vaccines
has been focusing on rough mutants lacking the major antigenic determinant, the O-
antigen.  However, the loss of O-antigen severely attenuates the survival of the organism
in the host and limits protection.  The most effective vaccine strains available such as
B. abortus S19 and B. melitensis Rev-1 have several limitations, not the least of which is
virulence in humans.  In an effort to identify vaccine candidates with enhanced efficacy
and improved safety, we have explored protection induced by attenuated mutants with
different survival characteristics, the rapidly clearing virB10 (BA114) and the longer-
persisting gcvH (BA102) mutants.  The results in this study suggest that the persistence
of the vaccine candidate in the mouse enhances long-term protection.  The gcvH mutant
induced significant levels of protection at 8, 16 and 24 weeks post-vaccination.  Even
though the protection against challenge began to decline from 16 to 24 weeks post-
vaccination for both candidates, BA102 still induced a significant level of protection.
Both vaccine candidates appeared to elicit a TH1 memory response in the BALB/c
mouse model as judged by the levels of IgG2a and IgG1 in the sera of vaccinated mice
and the induction of IFN-gamma and IL-2 in splenocytes obtained from vaccinated mice
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in response to heat-killed Brucella or cell lysates.  Surprisingly, the production of IL-10,
a TH2 cytokine, was also enhanced.
Introduction
The vaccination against bovine brucellosis with live attenuated smooth B.
abortus strain S19 is used in most of the world because it has been useful for the control
and eradication of this disease (101), (102).  This vaccine is effective in conferring
protection against virulent strains of B. abortus.  However, there is a number of
disadvantages.  Strain S19 can cause abortion in pregnant animals and is still fully
virulent for humans.  In addition, it is difficult to differentiate between vaccinated and
naturally infected animals, because S19 induces a humoral response that is similar to the
response after natural infection, thus hampering procedures for the detection of infected
animals by serological testing.  In order to avoid these drawbacks, a stable,
lipopolysaccharide O-antigen-deficient mutant of virulent B. abortus S2308 was
developed (124).  This rough, rifampin-resistant, attenuated variant is designated as
RB51 and is currently being used in many countries as an alternative vaccine to B.
abor tus  S19 because this strain does not induce antibodies to B r u c e l l a
lipopolysaccharide O-antigen.  Thus, it is possible to discriminate between infected and
vaccinated animals.  B. abortus RB51 retains the ability to confer protection against
infection with pathogenic strains in both mice and cattle (45), (73), (91), (104), (135),
(134), (131).  However, the duration of protective efficacy is short-lived because RB51
can only persist for a short period in the spleens of mice vaccinated by intraperitoneal
36
injection.  Since protection against Brucella infection requires a long-lived cellular
immune response, the survival of the vaccine strain is therefore crucial for the
development of a protective cellular immune response against B. abortus in cattle.
Two mutant strains (gcvH and virB10) among 14 attenuated B. abortus mutants
isolated previously by signature-tagged mutagenesis (STM) were further analyzed for
possible use as live attenuated vaccines.  Selection of these two mutants was based on
contrasting differences in the survival phenotype.  B. abortus BA102 harbors a mini-Tn5
kanamycin cassette insertion in gcvH that exhibits a defect in chronic persistence in the
mouse model (69), but no severe reduction on the intracellular survival within
macrophages in vitro.  The insertional mutation in BA102 is predicted to cause
premature transcriptional termination of gcvH and abolishment of gcvP expression, and
thus, resulting in the absence of a functional enzyme that may be essential for the
survival of intracellular pathogens at reduced oxygen concentration (147), (149), (151).
Consistent with an anaerobic state for Brucella is the observed requirement for
cytochrome bd oxidase during intracellular growth (46), (81), (82).
Defective persistence in mice was also observed for BA114, the virB10 mutant of
B. abortus carrying a mini-Tn5 insertion in the virB10 gene of the type IV secretion
system (69).  Type IV secretion systems (T4SS) are found in several mammalian and
plant pathogens including Bordetella pertussis, Helicobacter pylori and Agrobacterium
tumefaciens, (27).  In the BALB/c mouse model, the defective virB10 mutant (BA114)
exhibited a severe reduction in numbers as early as two weeks post-infection (69).  In
murine bone marrow-derived macrophages and J774A.1, B. abortus and B. melitensis
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mutants defective in T4SS were killed in the phagolysosomal compartment, suggesting
that unlike the wild type these mutants were unable to inhibit phagosome maturation
(22), (40), (146).
Both mutants of B. abortus, BA102 (gcvH) and BA114 (virB10), exhibit no
growth defects when grown in liquid or on solid media (69).  Therefore, attenuation in
the mouse model was not simply the result of defects in growth or replication.
Furthermore, both mutants did not require supplements when grown on Brucella
minimal media, suggesting that the transposon insertions in gcvH and virB10 do not
render them auxotrophic.
The present study focuses on an organism such as the gcvH mutant of B. abortus
that survives and replicates within the host for extended periods, presumably preventing
phagolysosomal fusion yet is incapable of persisting at late times due to a failure to
adapt to the changing environmental conditions, which are not experienced by bacteria
infecting macrophages in culture.  For comparison, an in vivo attenuated virB mutant of
B. abortus, which fails to prevent fusion and hence is rapidly degraded, has been
selected.  The duration of survival of both mutants is expected to be sufficient to
stimulate an adaptive immune response; however, differences in the replicative burst and
the duration of exposure are expected to provide significantly different protective
immune responses against wild type S2308.
As a result, the longer-lived gcvH mutant (BA102) elicited higher levels of TH1-
associated cytokines (IFN-gamma and IL-2) and proliferative responses of splenocytes,
which persisted up to 24 weeks post-inoculation.  In contrast, the shorter-lived virB10
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mutant (BA114) only induced a significant level of IFN-gamma during the later phase of
infection, and additionally, BA114 elicited a transient TH1 response that was observed
between 8 and 24 weeks post-vaccination.  Surprisingly, neither BA102 nor BA114
mutant elicited significant splenomegaly at 8, 16, and 24 weeks post-inoculation.  Taken
together, the gcvH mutant or similar longer-surviving strains offer the best choice for
long-lasting protective immunity.  Side effects associated with persistence must be
eliminated in order to make them safe for human use.
Materials and Methods
Bacteria and bacterial products.  Wild-type B. abortus S2308 and vaccine strain 19
were obtained from B. L. Deyoe, National Animal Disease Center, and Ames, Iowa,
respectively.  Strains BA102 and BA114, attenuated mutants containing a single
insertion of mini-Tn5 kanamycin cassette in gcvH and virB10, respectively, as described
elsewhere (69) were derived from signature-tagged mutagenesis of B. abortus S2308.
Strain BA582 is an attenuated mutant of B. abortus containing a wild-type Tn-5
insertion in cydB (46).  All strains (Table 3) were grown on Brucella agar with or
without kanamycin (100 mg/mL) for 3 days at 37°C.  For infection of mice, bacteria were
harvested from plates into PBS (pH 7.4) and ten-fold serial dilutions were made to
obtain the appropriate inoculum (107 CFU/mL mutant or 105 CFU/mL S2308).  For in
vitro growth and macrophage survival assays, isolated bacterial colonies grown on plates
were used to inoculate 5-mL tryptic soy broth (TSB) containing the appropriate
antibiotics followed by a 24-h incubation at 37°C in a rolling drum.  The 24-h liquid
39
cultures were then used to prepare 48-h liquid cultures (a 1:50 dilution of the 24 h
culture in 5 mL of fresh TSB containing the appropriate antibiotics).  The bacteria from
a 48-h culture were pelleted by centrifugation for 30 sec at 2500 x g, washed twice with
PBS (pH 7.4) and resuspended in PBS (pH 7.4) to adjust the concentration to 5 X 109
CFU/mL based on turbidity measurements using the Klett meter.  For ELISA, bacterial
suspensions in PBS (pH 7.4) were heat-killed overnight at 68°C.  Heat-killed B. abortus
(HKBA) was sonicated to generate a bacterial cell lysate (BACL) containing
approximately 1.7 mg of protein/mL as estimated by the BioRad protein dye (California)
and SoftMax 2.02 (California).  All work with live B. abortus was performed in a
Biosafety Level-3 containment facility following the Centers for Disease Control-
National Institutes of Health guidelines appearing in the BMBL 4th edition (116).
Tissue culture and macrophage survival assay.  The macrophage-like cell line
J774A.1 was obtained from the ATCC and maintained as frozen stock in 40% DMEM
(high glucose, 4500 mg/L) containing 1% (v/v) non-essential amino acids, 7.3 mM L-
glutamine, 10% (v/v) DMSO, and 50% (v/v) fetal bovine serum at –180°C. The J774A.1
cells were grown in complete DMEM (Sigma, 4500 mg glucose/L, 25 mM HEPES,
without L-glutamine) containing 10% (v/v) heat-inactivated fetal calf serum, 1% non-
essential amino acids, and 7.3 mM L-glutamine in the presence of 100U penicillin and
10 mg streptomycin (Difco) for 3 days at 37°C, 5% CO2 or until the plate was confluent.
Cells were collected and resuspended in fresh serum-containing DMEM without
penicillin-streptomycin and the concentration was adjusted to approximately 4 x 105
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cells/mL.  Each well of the 24-well microtiter plate contained approximately 2 x 105
cells.  The cells were then incubated for 24 h at 37°C, 5% CO2.  Before the introduction
of bacteria, media were replaced with serum-free DMEM without penicillin-
streptomycin.  Each set of triplicate wells received 2.5 x107, 5 x 107, or 7.5x107 CFU of
bacterial strain and cells were incubated for 20 min at 37°C, 5% CO2.  To synchronize
infection, cells were centrifuged for 5 min at 411 x g, 10°C.  Old media were replaced
with fresh complete DMEM containing 15mg/mL gentamicin.  For t=0 h, medium
containing 15mg/mL gentamicin was removed after incubating at room temperature for 5
min, followed by washing three times with PBS (pH 7.4) to remove extracellular
bacteria.  Infected macrophages were lysed by the addition of 500 mL of 0.5% (v/v)
Tween-20.  The lysate was transferred to a clean tube and each well was rinsed with an
additional 500 mL of PBS (pH7.4), which was then added to the tube containing the
initial lysate.  Ten-fold serial dilutions were performed on the inoculum and each lysate,
and dilutions were plated on TSA or TSA containing the appropriate antibiotics.
Macrophage survival assay for each mutant was performed in 3-4 separate experiments.
Infection of mice.  Groups of eight 6-to-8-week-old female BALB/c mice (Jackson
laboratories, Maine) were infected intraperitoneally (i.p.) with a dose of 106 CFU of the
mutant per animal.  Non-vaccinated, control mice received only PBS (pH 7.4)
intraperitoneally.  At various time points (8, 16, and 24 weeks post-vaccination), sera
were collected to test for antibody before the 21-days of treatment with doxycycline
(DOX) (50 mg doxycycline/ kg of body weight per 12 h, oral).  In order to determine the
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length of time required for doxycycline to clear from the mice, DOX-treated animals
were given a challenge infection of S2308 at 2, 10, and 15 days post-DOX treatment.  A
control group of untreated animals also received a challenge infection of S2308.  The
clearance of doxycycline within the host was established by similar levels of recovered
splenic S2308 observed at one week post-challenge in animals of the 15-day-post-DOX-
treatment group and in those of the untreated group.   In selected experiments, groups of
four-to-five vaccinated and non-vaccinated mice were sacrificed two weeks after the
DOX treatment, in order to obtain spleen cells for proliferation and cytokine production
assays.  Sera were also collected and spleens were aseptically removed and weighed.
Splenocytes were harvested from one half of the spleen; the other half was homogenized
in 250 mL of PBS (pH 7.4) and serial ten-fold dilutions were plated on TSA or TSA
supplemented with kanamycin (100 µg/mL) plates in order to determine the number of
viable brucellae remaining in the spleens.  Other groups of vaccinated mice and the
control group of non-vaccinated animals after two weeks of DOX treatment received a
challenge infection of B. abortus S2308, in which each animal received a challenge dose
of 104 CFU S2308.  At one week post-challenge, sera were collected and mice were
sacrificed.  Spleens were then aseptically extracted, weighed and processed for bacterial
count.  Those of the S2308-infected groups were also included for comparison.
Detection of Brucella-specific antibodies.  Sera of vaccinated mice (5 mice per group)
were collected at two weeks after doxycycline treatment.  Sandwich ELISA was
performed in 96-well flat-bottom polystyrene microtiter plates (Costar, Massachusetts).
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Wells were coated with 10 µg of BACL and incubated for 3 h at 37°C.  Excess binding
sites were then blocked with 1% (w/v) casein (Fisher Scientific, Maryland) in PBS for 1
h at 37°C.  Wells were washed with PBS between steps to remove unbound materials.
The antigen-coated wells were incubated with serial two-fold dilutions of primary
antibodies (sera from mice) for 16 h at room temperature (25°C).  The plates were then
incubated with phosphatase-labeled goat anti-mouse immunoglobulins, IgG(H+L),
IgG1(g1), or IgG2a(g2a) for 20 h at room temperature using protocols obtained from
Southern Biotech (Alabama).  The values of IgG, IgG2a and IgG1 were calculated from
the cutoff values (IgG=0.737, IgG2a=0.150, and IgG1=0.151) that were generated as
follows.  Sera obtained from 5 (naïve) control animals were diluted 1:100 and detected
by standard ELISA procedure (20).  The cutoff value is the sum of the mean OD450-
readout result obtained from serum samples of 5 control animals plus 3 times the
average standard deviation.  For each sample, 2-fold serial dilutions were performed
before adding to the ELISA plate.  The titer was calculated by transforming the highest
2-fold dilution that has an OD450-readout value above the cutoff value to the titer log2.
Splenocyte proliferation and cytokine production.  One-half of individual spleens
from vaccinated/DOX-treated mice and naïve control animals were ground lightly (7).
After lysis of erythrocytes with ACK lysis buffer (150 mM NH4Cl, 10 mM KHCO3, 100
mM Na2EDTA, pH 7.2-7.4), cell suspension was washed three times in RPMI-1640
medium.  Then the concentration of cells was adjusted to 2 x 106 cells/ml with complete
RPMI-1640 containing 25 mM HEPES, 2 mM L-glutamine, 10% (v/v) heat-inactivated
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(for 30 min at 56°C) fetal bovine serum (Difco), and 5.5 x 105 M 2-mercaptoethanol in
the presence of 100U penicillin and 10 mg streptomycin (Difco).  For proliferation, 2
X105 cells were cultured with 2 mg of concanavalin A (ConA), 1 X 108 heat-killed B.
abortus S2308, or 1 µg of Brucella lysate in each well of a 96-well flat-bottom tissue
culture treated plate (Corning, New York) for 5 days at 37°C, 5% CO2.  Cells in control
wells received complete RPMI-1640 only (as background control).  On day 5, cultures
were pulsed with 1 µCi of [3H]-thymidine for 18 h.  Cells were then harvested onto glass
fiber filters (Packard).  These filters were placed into vials containing scintillation
cocktail, and incorporated radioactivity was measured by liquid scintillation counting in
Beckman LS6000 Series Scintillation System (California).  For cytokine production by
splenocytes, 4 x 106 cells were cultured as described in a 24-well tissue culture treated
plate (Costar, Massachusetts) for 3 days at 37°C, 5% CO2.  Cell suspensions were
harvested and assayed for cytokine levels.  Filtrates were analyzed by ELISA for IL-2,
IL-4, IL-10, and IFN-gamma using monoclonal antibody pairs (eBioscience, California).
Statistical methods.  For macrophage survival experiments, results obtained at t=24h
and 48h of the macrophage survival assay were calculated in relative to t=0 and
presented as CFU of t / CFU of t=0 ratios.  The significant differences between groups
were analyzed by the one-way ANOVA using Fisher’s LSD pairwise comparisons while
the differences in the survival of a strain between t=24 and t=48 were analyzed by the
Student’s t test of one-tailed distribution and two-sample equal variance.
For the in vivo experiments including the survival of mutants in the moue model
44
and the vaccine potential, data reported from spleens of immunized versus non-
immunized animals were expressed as mean CFU + standard error (SE); as noted,
culture-negative spleens were assigned a value of 1 CFU + 1 SE.  These data were
graphically presented as CFU of Brucella per spleen.  Spleen weights of immunized and
control mice were also recorded and the average spleen mass is calculated from groups
of four-to-five mice and presented in grams with +standard error.  Statistical analyses
were performed using the Student’s t test with one-tailed distribution and two-sample
equal variance.
For the measurements of IgG, IgG2a and IgG1, results obtained were presented
graphically as titer log2 + SE.  Statistical analyses of titers were performed using the
Student’s t test with one-tailed distribution and two-sample equal variance.
For the proliferation experiments and the cytokine profiling experiments, data
obtained from the [3H]-thymidine cultured-splenocytes were expressed as mean cpm.
Results of cytokine induction in (heat-killed B. abortus) HKBA-stimulated splenocytes
were calculated along with individual cytokine standards and graphically presented as
units (pg/mL) + SE.
Results
Growth characteristics of attenuated STM mutants.  STM mutants BA114 (virB10)
and BA102 (gcvH), were originally characterized as early and late mutants due to
survival defects at two weeks and eight weeks, respectively (69). Our previous results
showed that these two mutants did not differ from the wild type in growth on either
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Gerhardt’s minimal medium or in TSB (69).  We were therefore interested in
determining whether the different survival characteristics in mice correlated with the
differences in the ability to survive within macrophages. The in vitro growth in
macrophages was evaluated using the murine macrophage-like cell line J774.A1.  The
macrophage-killing assays revealed that BA102 and BA114, as well as all other strains
tested including BA582, which is defective in cytochrome d oxidase (46), and the
control strains S19 (vaccine) and S2308 (challenge), were reduced by approximately 2
logs at 24 h after infection (Table 3, Fig. 3).  However, CFU of S19 and S2308 strains
increased significantly between 24 and 48 h (p<0.0212 and 0.0210, respectively) while
much less growth was apparent with BA102 and BA582 (p<0.0465 and 0.0804,
respectively).  In contrast, the bacterial load of BA114 in macrophages continued to
decline (one-log reduction) until 48 h post-infection.  The results show that BA102
(gcvH), BA582 (cydB) and S19 are moderately attenuated for growth in macrophages,
while BA114 (virB10) has a more marked defect in the intracellular persistence.
Survival of gcvH and virB10 mutants in the mouse model.  Long-term persistence in
the host of fortuitously isolated vaccine strains including B. abortus S19 and
B. melitensis Rev-1 has been offered as one explanation for their success in stimulating
immune protection.  In order to compare the vaccine potential of strains with similar
genetic backgrounds yet distinctly different survival characteristics, the persistence of
the STM mutants, BA102 (gcvH) and BA114 (virB10), in the spleen was evaluated using
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Table 3:  Brucella abortus strains involved in the study
Strain Description, Source/Reference
S2308 Wild-type B. abortus (biovar 2) that was used as the parental strain
for STM mutant bank, obtained from B. L. Deyoe, National Animal
Disease Center.
S19 B. abortus vaccine strain 19 obtained from Ames, Iowa.
BA102 B. abortus signature-tagged mutagenesis (STM) mutant carrying a
single mini-Tn5 cassette insertion in the gcvH gene (69).
BA114 B. abortus signature-tagged mutagenesis mutant carrying a single
mini-Tn5 cassette insertion in the virB10 gene (69).
BA582 B. abortus cydB::Tn5 (46).
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Fig. 3.  Intracellular survival of B. abortus STM mutants.  Survival of each Brucella
strain (B. abortus S2308, BA102 (gcvH), BA114 (virB10), BA582 (cydB), and vaccine
S19) in the murine macrophage-like cell line J774A.1 is graphically presented by the
ratio of the average CFU at t to the average CFU at t=0.  The average CFU recovered
from infected macrophages at each t was calculated from a triplicate set and the assay
was performed as 3-4 separate experiments.  In each experiment, 107 CFU per strain was
used to infect 105 macrophages, and t=0 was taken after the 5-min room temperature
incubation.  Statistical analyses were performed as follows.  One-way ANOVA followed
by the Fischer’s LSD pairwise comparisons was used to compare the differences in the
ability to survive intracellularly between strains (S2308 vs. BA102, BA114, BA582, and
S19); the p-values <0.05 were considered statistically significant.   The Student’s t test
with one-tailed distribution and two-sample equal variance was used to compare the
differences in the survival of a strain within the macrophage between t=24 and t=48; *,
p<0.05; **, p<0.01; ***, p<0.005.
1.00E-05
1.00E-04
1.00E-03
1.00E-02
1.00E-01
1.00E+00
S2308 BA102 BA114 BA582 S19
Strain
C
F
U
 a
t 
t 
/ C
F
U
 a
t 
t=
0
t=24/t=0 t=48/t=0
*
*
48
the BALB/c mouse model.  In an effort to compare strains for potential vaccine use,
strains exhibiting various survival characteristics were chosen.  The cydB (BA582) and
virB10 (BA114) mutants have been shown to exhibit a large reduction in numbers of
splenic brucellae between one and two weeks after inoculation; and by 8 weeks post-
infection few, if any, bacteria were recoverable ((46), Fig. 4).  In contrast, the gcvH
(BA102) mutant dramatically decreased in number in the spleens of mice over the first
16 weeks post-inoculation and then cleared much more gradually over the next 8 weeks,
i.e., showing a slight decrease in numbers between 16 and 24 weeks post-inoculation.
Thus, the decline in CFU of BA102 distinguished it from the early-clearing BA114,
which was below the level of detection by 16 weeks post-inoculation.
Vaccine potential (induced protective immunity) of attenuated mutants.  The
attenuated in vivo survival of STM mutants is an attractive attribute for live vaccine
candidates against brucellosis.  To be effective, live attenuated vaccines must persist
long enough to elicit protective immunity, yet they should be cleared as quickly as
possible to avoid unnecessary side effects.  In order to determine whether greater
persistence correlates with greater protection, the ability of selected mutants to protect
mice against a wild-type B. abortus 2308 challenge infection examined.  Since both the
duration of bacterial colonization and the level (CFU) of colonization of these strains
differed, (Fig. 4), it was difficult to relate the potential differences in the level of
protection among these strains solely to the level of colonization or the duration of
colonization by the vaccine strain that exhibit such a wide range of in vivo persistence
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Fig. 4.  Survival curves of individual STM mutants in BALB/c mice at 8, 16, and 24
weeks post-vaccination.  (A)followed by 21 days of doxycycline treatment (50 mg
DOX/kg of body weight per 12 h, oral),  (B)without doxycycline treatment.  Each animal
was inoculated with 106 CFU per mutant strain or 104 CFU S2308.  At 8, 16, and 24
weeks post-inoculation, animals were either treated not treated with doxycycline for 21
days.  Two weeks post-treatment, all mice were sacrificed and spleens were extracted
aseptically for bacterial counts.  Each data point represented the average CFU recovered
from spleens of 4-5 mice.  Statistical analysis was performed using the Student’s t test
with one-tailed distribution and two-sample equal variance; the vertical bars show the
standard errors.  STM, signature-tagged mutagenesis; p.v., post-vaccination.
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these two variables. In order to reduce the bacterial burden of the persisting strain prior
to challenge and set a defined period of vaccine strain colonization, oral treatment with
doxycycline (DOX) was administered daily for 21 days at 8, 16, or 24 weeks post-
vaccination (Fig. 5).  To ensure that low levels of DOX that might persist after cessation
of the treatment would not affect the persistence of the challenge inoculum, a control
experiment was performed, in which groups of mice that had been treated with DOX two
weeks previously or untreated control animals were inoculated with 104 CFU of B .
abortus 2308.  The survival of the challenge strain 2308 in animals at two weeks post-
DOX treatment was not significantly different from that in the untreated animals (Fig.
6).
The level of protection conferred by vaccination with BA114 (virB10), BA102
(gcvH), BA582 (cydB) or Strain 19 was compared by enumeration of splenic S2308 at
one week after challenge (Fig.7).  The control group of unvaccinated animals showed a
recovery of nearly 107 CFU of S2308 per spleen one week post-challenge, which is
approximately a 3-log increase in the bacterial load in comparing to the inoculum dose.
In contrast, BA102- and BA114-vaccinated animals of the 8-week-post-vaccination time
point exhibited significantly lower splenic loads of S2308 at one week post-challenge
when compared to those of the control group (p-values:  0.0077 and 0.0079,
respectively).  At 16 weeks post-vaccination, both BA102- and BA114-induced
protection against challenge reached a maximum with no discernable difference between
these two mutants in the level of protective immunity, despite an almost 2-log difference
and bacterial burden.  Therefore, an experimental design was used to allow separation of
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Fig. 5.  The time line of vaccination, doxycycline treatment, and challenge infection with
B. abortus S2308.  p.v., post-vaccination; doxycycline treatment, 50 mg DOX/kg of
body weight per 12h (oral).
Day 1
24 mice vaccinated with BA102 or BA114,
8 mice vaccinated with BA582 or S19, 106 CFU per animal,
and (as a negative control) 24 mice received PBS (pH 7.5).
Day 148
4 from each vaccinated
(BA102 or BA114) and
control group were
sacrificed for assays and
bacterial counts
4 from each vaccinated
(BA102 or BA114) and
control group received
S2308 (104 CFU per animal)
Day 203
4 from each vaccinated
(BA102 or BA114) and
control group were
sacrificed for assays and
bacterial counts
4 from each vaccinated
(BA102 or BA114) and
control group received
S2308 (104 CFU per animal)
Day 91
4 from each vaccinated
(BA102 or BA114) and
control group were
sacrificed for assays and
bacterial counts
4 from each vaccinated
(BA102 or BA114) and
control group received
S2308 (104 CFU per animal)
Day 98
Sacrificed and enumerated
splenic brucellae
Day 155
Sacrificed and enumerated
splenic brucellae
Day 210
Sacrificed and enumerated
splenic brucellae
Day 56 (8 wks p.v.)
8 from each vaccinated
(BA102 or BA114) and
control group received DOX
treatment for 21 days
(Day 56-Day77)
Day 113 (16 wks p.v.)
8 from each vaccinated
(BA102 or BA114) and
control group received DOX
treatment for 21 days
(Day 113-Day134)
Day 168 (24 wks p.v.)
8 from each vaccinated
(BA102 or BA114) and
control group received DOX
treatment for 21 days
(Day 168-Day189)
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Fig. 6.  Doxycycline clearance.  (A) Time course study to determine the clearance of
doxycycline from the host, (B)The effect of doxycycline in mice at 2, 10, and 15 days
after treatment.  Groups of 6-to-8-week old female BALB/c mice were treated for 21
days with doxycycline (50 mg DOX/kg of body weight per 12 h, oral).  At 2, 10, and 15
days after treatment, animals were inoculated with B. abortus S2308.  As a control,
untreated mice were also received challenge infection with S2308.  One week post-
challenge, animals were sacrificed for bacterial counts of splenic brucellae.  Statistical
analysis was performed using the Student’s t test with one-tailed distribution and two-
sample equal variance.  The vertical bars show the standard errors.  The p-values
indicate the differences between the untreated group and the group that received DOX
treatment 2, 10, or 15 days previously:  *, p<0.05; **, p<0.01.
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Fig. 7.  Recovery of B. abortus S2308 from vaccinated animals one week after
challenge.  At each time point (8, 16, and 24 weeks post-vaccination), animals were
treated with doxycycline (DOX) for 21 days (50 mg DOX/kg of body weight per 12 h,
oral).  Animals of the unvaccinated control group were also received DOX treatment.  At
2 weeks post-treatment, groups of 4-5 mice received a challenge infection with B.
abortus S2308 intraperitoneally at a dosage of 104 CFU per animal.  Following one week
post-challenge, mice were sacrificed and bacteria were harvested from spleens.  The
total CFU of S2308 recovered was calculated from the difference between the total CFU
on TSA plates and the total CFU on TSA containing kanamycin.  Statistical analysis was
performed using the Student’s t test with one-tailed distribution and two-sample equal
variance; the vertical bars show the standard errors.  The p-values indicated the
significant differences between the control/DOX group and the mutant-vaccinated/DOX-
treated group:  *, p<0.05; **, p<0.01; ***, p<0.005.
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in the persisting bacterial load between these strains prior to challenge.  However, by 24
weeks post-vaccination, the BA102-induced protective immunity against challenge
remained significantly high at approximately 2-logs greater than the protection induced
by BA114 mutant.  Nevertheless, the recovered splenic S2308 load in BA114-vaccinated
mice of the 24-week post-vaccination time point was reduced significantly when
compared to naïve animals at one week after challenge (p-value:  0.0210).  For
comparison, S19-vaccinated mice exhibited levels of protection intermediate to those of
BA102- and BA114-vaccinated animals.
In mice, infection with Brucella has been shown to induce an inflammatory
response and trigger the recruitment of macrophages in the spleen, resulting in
splenomegaly.  Hence, spleen mass, as a result of live-strain inoculation, can serve as an
indicator for the severity of the infection, which often corresponds to the bacterial
burden.  Thus, mice inoculated with attenuated organisms are expected to exhibit
reduced splenomegaly while those inoculated with S2308 will show a pronounced level
of spleen-enlargement.  Overall, vaccinated mice after receiving a challenge infection
exhibited a greatly reduced splenomegaly when compared to the unvaccinated animals
after challenge, i.e., 25-50% and 100% increase in spleen mass, respectively.  However,
measuring protection by the degree of splenomegaly proved to be less sensitive than that
by enumeration of brucellae; particularly, when compared the BA102-inoculated to the
BA114-inoculated animals, those vaccinated with BA114 appeared to show better
protection against splenomegaly than against colonization (Table 4, Fig. 7).
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Table 4:  Spleen mass of vaccinated/DOX-treated BALB/c mice
Spleen mass (g) before challenge1 Spleen mass (g) post-challenge2
Group 8 wks
p.v.
16 wks
p.v.
24 wks
p.v.
8 wks
p.v.
16 wks
p.v.
24 wks
p.v.
Control 0.143 +0.022 0.324 +0.051
BA102 0.163
+0.007
0.133
+0.030
0.188
+0.025
0.186
+0.018
0.207
+0.008
0.266
+0.023
BA114 0.0860
+0.010
0.115
+0.014
0.116
+0.010
0.162
+0.020
0.130
+0.011
0.136
+0.028
S2308 0.220
+0.036
0.190
+0.017
0.178
+0.018
N/A
BA582 N/A N/A 0.147
+0.029
N/A N/A 0.203
+0.017
S19 N/A N/A 0.145
+0.015
N/A N/A 0.192
+0.028
18, 16, or 24 weeks post-vaccination plus 21 days of doxycycline treatment and two
additional weeks post-doxycycline treatment.
2One week post-challenge.
p.v., post-vaccination.
N/A, no animals were tested.
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Antibody subclass as a measure of T-helper cell driven response.  We have
demonstrated that two STM mutants BA102 (gcvH) and BA114 (virB10), exhibiting
different survival characteristics in the mouse model and the murine macrophage-like
cell line J774.A1, stimulated protection against wild-type B. abortus S2308.  However,
BA102 (gcvH), the longer-persisting mutant, appears to provide a longer-lasting
protective immunity.  Therefore, in order to characterize factors contributing to this
increased protection, the humoral response IgG isotypes and the cellular responses
including lymphocyte proliferation and cytokine profiles of T cell-mediated immune
responses (TH1/TH2) were evaluated in vaccinated mice after the DOX treatment and
after challenge.  Brucella-specific IgG was present at similar levels in all vaccinated
groups before and after doxycycline treatment (Fig. 8).  The levels of IgG2a isotype in
vaccinated animals showed no significant changes throughout the experiment (Table 5).
However, the IgG1 levels were significantly different between animals vaccinated with
BA114 and those vaccinated with BA102.  At 24 weeks post-vaccination and followed
by 21 days of DOX treatment, BA114-vaccinated mice exhibited a significant increase
of IgG1 while BA102-vaccinated animals showed a reduction in IgG1.  In general, when
IgG2a >IgG1, the response will favorably shift toward TH1 while a TH2-driven response
is ensured when IgG2a<IgG1 (119).  Taken together, unlike BA102, the rapidly clearing
mutant BA114 appeared to elicit an immune response that has characteristics of TH2 at
24 weeks post-vaccination, which may reflect the loss of memory response over time
and hence leading to the decline in protective immunity observed in the BA114-
vaccinated groups.
58
Fig. 8.  Anti-Brucella antibody (IgG) in vaccinated BALB/c mice before and after
doxycycline treatment.  At 8, 16, and 24 weeks post-vaccination (Day 56, 113, and 168,
respectively), sera from vaccinated mice were collected and stored at –70°C until use.
Two weeks post-doxycycline treatment (Day 91, 148, and 203, respectively), sera were
collected.  Sandwich ELISA using phosphatase-labeled goat anti-mouse IgG(H+L) was
performed and the values of IgG were calculated from the cutoff value of 0.737, which
was generated from sera of five naïve control animals.  Statistical analysis was
performed using the Student’s t test with one-tailed distribution and two-sample equal
variance.  The vertical bars indicate the standard errors.
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Table 5:  Detection of Brucella-specific IgG isotypes
Naïve BA114 BA102 BA114 BA102
1Before Challenge 8 wks p.v. 8 wks p.v. 24 wks p.v. 24 wks p.v.
IgG2a/IgG1 0.7 1 1.03 0.8 1.1
IgG2a 11.2 11.4 17 12.2 15.6
IgG1 16 11.2 16.6
1*15.6 1*13.4
2After Challenge
IgG2a/IgG1 1.1
2*1.3 2*1.3 2*1 2*1.3
IgG2a 8.2 13.2 16.6 15.8 15.6
IgG1 7.6 12.4 14 16 12.4
18 or 24 weeks post-vaccination (8, 24 wks p.v.) plus 21 days of doxycycline treatment
and two additional weeks post-doxycycline treatment.
2One week after challenge.
1*Significant differences before challenge between the vaccinated groups of the 8-week
post-vaccination and the 24-week post-vaccination times points; p-values:  0.0011
(BA114) and 0.0027 (BA102).
2*Significant differences after challenge between the vaccinated group and the control
group (naïve animals).
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Cytokine production.  Cytokine induction (IL-2, IL-4, IL-10, and IFN-gamma) was
evaluated using sandwich ELISA of supernatants from lymphocytes.  By eight weeks
post-inoculation, mice infected with the attenuated BA102 as well as S2308 exhibited
significantly increased production of the TH1 cytokines (IFN-gamma, and IL-2), yet no
significant induction was observed for IL-4 in response to Brucella lysate (Fig.9A, B,
C).  However, by 24 weeks post-vaccination splenocytes from all vaccinated mice
exhibited a slight change in cytokine profiles showing a significant increase in the TH2-
cytokine IL-10 (Fig. 9D).  The increase in IL-10 does not appear to parallel the observed
changes in the IgG2a and IgG1, which showed a TH1 memory response using sera
obtained from vaccinated mice.  It is not clear whether the difference could be the result
of comparing in vivo and in vitro readouts in the protocols that employ viable organisms
(in vivo) and either heat-killed organisms or lysates (in vitro).
Lymphocyte proliferative responses.  The T cell-mediated memory immunity resulting
from vaccination with attenuated mutants was evaluated in response to either heat-killed
B. abortus (HKBA) or B. abortus cell extracts (BACL).  All animals including all
vaccinated groups, S2308-infected group, and the unvaccinated control group were
given daily doses of doxycycline for three weeks in helping to modulate the bacterial
load of the inoculated strain, particularly, the more persistent gcvH mutant, and were
then left untreated for two weeks to permit the clearance of the antibiotic.  Although no
significant differences in lymphocyte proliferation response were observed between the
BACL and HKBA-stimulated lymphocytes, HKBA-stimulation provided more
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Fig. 9.  Induction patterns of cytokines in BALB/c mice at 8 weeks and 24 weeks post-
vaccination followed by 21 days of doxycycline (DOX) treatment (A)IFN-gamma,
(B)IL-2, (C)IL-4, and (D)IL-10.  Splenocytes were harvested at 2 weeks post-DOX
treatment and cultured for 3 days.  ELISAs for IFN-gamma, IL-2, IL-4, and IL-10 were
performed using monoclonal antibody pairs.  Statistical analysis was performed using
the Student’s t test with one-tailed distribution and two-sample equal variance.  The
vertical bars show the standard errors.  The p-values indicated the significant differences
in cytokine induction observed between the control (unvaccinated)/DOX-treated animals
and the vaccinated/DOX-treated animals:  *, p<0.05; **, p<0.01; ***, p<0.005.
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consistent results and will be discussed here.  Lymphocytes from all groups of S2308-
infected or attenuated mutant-vaccinated mice consistently responded to heat-killed
brucellae (HKBA) over the course of the experiment (Fig. 10).  At 24 weeks post-
infection, T cell-mediated memory responses in animals vaccinated with two other
strains, BA582 mutant and the vaccine strain B. abortus S19, were also evaluated.  Both
strains, BA582 and S19, are attenuated in mice with different rates of clearance from the
spleens.  All vaccinated animals and S2308-infected mice of the 24-week post-
vaccination time point showed a strong lymphocyte proliferation response, despite the
differences in the survival characteristics of each inoculum strain.  The greatest
proliferation response was observed in animals vaccinated with a longer-surviving
mutant BA102 as well as in those infected with S2308.  Mice vaccinated with S19,
BA114, and BA582 also exhibited lymphocyte proliferation suggesting that these
strains, which clear as quickly as 2 weeks post-inoculation, exhibit a sufficient burst
during the expansion phase to elicit a long-term memory response.
Discussion
Since both M. tuberculosis and Brucella spp. are intracellular pathogens causing
chronic diseases, it is tempting to speculate that chronic brucellosis may be similar to
tuberculosis, i.e., with “non-replicating” organisms in the host.  Lack of a functional
enzyme of the glycine cleavage system renders the gcvH mutant (BA102) incapable of
long term persistence in mice, yet has no effects on in vitro growth (69). This non-
auxotrophic mutation resulted in an inability to maintain chronic infections in vivo and
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Fig. 10.  Proliferation of splenocytes in BALB/c mice.  (A)8 weeks post-vaccination,
(B)24 weeks post-vaccination followed by 21 days of doxycycline treatment.  Within
each vaccinated/DOX-treated group of 4-5 mice, unstimulated splenocytes cultured in
[3H]-thymidine were included as negative controls to compare to those that were
stimulated with the heat-kileed S2308 (HKBA), or Concanavalin A (ConA) for 3 days.
Results obtained from HKBA-stimulated splenocytes of the control group establish the
threshold value for the proliferation response (4412.07+829.07 cpm).  Statistical analysis
was performed using the Student’s t test with one-tailed distribution and two-sample
equal variance.  The vertical bars show the standard errors.  The p-values indicate the
significant differences between HKBA-stimulated control (unvaccinated) groups and
HKBA-stimulated mutant-vaccinated groups:  *, p<0.05; **, p<0.01, ***, p<0.005.
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also prevented normal replication of the mutant in macrophage culture supporting the
contention that chronic infections of hosts are a result of parasitism of macrophages (17)
(74).  However, differences in the intracellular survival of BA102 within the
macrophage were not as apparent compared to those of the other in vivo attenuated
mutants (Figure 1).  All strains tested exhibited a decline in numbers (between 90 and
99%) over the first 24 hours of infection.  But the differences were most apparent over
the next 24 hours during which the virB10 mutant (BA114) continued to decline while
the parental strain S2308 recovered in numbers.  This observation is in agreement with
several studies of type IV secretion system (T4SS) in Brucella, in which the virB operon
plays a critical role in the intracellular multiplication and virulence (79) (127).  The
T4SS of B. abortus has been shown to be required for modulation of the intracellular
trafficking within HeLa cells (29), but not evasion of nitrosative or oxidative bactericidal
killing by macrophages (136).
In contrast, inactivation of the gcv operon is expected to prevent adaptation to
low oxygen environments.  Consistent with an anaerobic state for Brucella is the
observed requirement for cytochrome bd oxidase during intracellular growth (46).
Under conditions of reduced oxygen found in inflammatory and necrotic tissues, glycine
dehydrogenase may serve to regenerate NAD from a reduced form, which provides ATP
to support the completion of a final cycle of DNA synthesis before the shutdown of
replication, and thus may be a factor contributing to the latency of the disease (151)
(149).  This may explain why BA102 only persisted in the mouse spleens as long as
24weeks post-infection.  The mutation in gcvH also appears to cause growth restriction
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of the mutant in the macrophage, despite the presence of a functional T4SS.  Such
growth restriction has been observed in wild-type E. coli strains harboring non-
functional selenolipoylated H-protein of the glycine cleavage system, in which both of
the sulfur atoms of the protein were replaced by selenium atoms (57).  Taken together,
the presence of a functional glycine cleavage system is vital to the survival of Brucella
in vivo and thus, is consistent with the need for additional factors for virulence.
Having two mutants with similar genetic backgrounds and possessed of different
survival characteristics provided an opportunity to compare the vaccine potential with
regard to the persistence of the strain. The efficacy of these live vaccine candidates to
induce protection was also accompanied by a reduced splenomegaly.  Both mutants
carrying defined mutations, which led to reduced persistence in the host, have the ability
to provide protection against wild type B. abortus and yet cause very minimal, if any, in
the host.
To better understand the differences in protective immunity induced by these
mutants, the fundamentals of host immune responses were examined and compared.
The host antibody response showed no differences in IgG levels between animals
vaccinated with the persistent BA102 and those vaccinated with the short-lived BA114.
All vaccinated animals exhibited a constant level of anti-Brucella antibody, IgG,
throughout the course of the study.  This result indicates that the Brucella antigen
remains in circulation for an extended period even after bacteria including those of the
short-lived BA114 are cleared from the host.  A similar observation has been
documented in patients clinically cured of acute brucellosis, in which Brucella
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antibodies persisted for more than 2 years after successful treatment and clinical cure
(2).
Typically, during the course of an immune response, different immunoglobulin
classes and subclasses are expressed.  Initially, IgM is secreted and IgG levels
subsequently increase.  In the presence of IL-4, a product of TH2 cells, B cells switch
from IgM to IgG1 secretion.  In contrast, IFN-gamma, a product of TH1 cells, is
associated with switching from IgM to IgG2a.  Thus, stimulation of TH1 or TH2 cells
results in expression of different immunoglobulin classes and isotypes.  Live and heat-
killed brucellae have been shown to elicit TH1-type host responses in both humans and
mice, (137) (156, 157).
In this study, the evaluation of the adaptive immune response focused on the
development of TH1 vs. TH2 immune responses, through an examination of the IgG2a and
IgG1 levels and the cytokine profiles.  Vaccination with either short-term or long-term
surviving mutants appeared to favor a TH1 memory response, which is characterized by
the steady levels of IgG2a and thus, consistent with pattern in all Brucella-inoculated
animals, i.e., IgG2a>IgG1.  However, by 24 weeks post-vaccination, the IgG1 levels in
BA114-vaccinated animals were significantly increased.  This sudden change observed
in the IgG1 isotype might be a result of the diminution of TH1 response.  A transient
acquired cellular immunity has also been observed in C3H mice upon the clearance of
bacteria from tissues, despite the fact that the C3H mouse model is more resistant to
Brucella infection than the BALB/c model (106), (155).  Recently, the diminution of
TH1 cytokine production in humans with chronic brucellosis was reported (60).
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There are two possibilities that may help to explain the aforementioned switch in
T helper cell response.  First, at 24 weeks post-inoculation no live brucellae were present
in the mice inoculated with the more rapidly cleared BA114, and thus, the host system
may have resumed its original state of which the BALB/c mouse model has been shown
to be a TH2-driven response model (23), (52).  The fact that the IgG2a/IgG1 ratio actually
increased following challenge even at 24 weeks post-vaccination is consistent with a
residual TH1 memory response.  Secondly, the absence of IL-2 and the late induction of
IFN-gamma might be another major contributing factor that allows a more favorable
shift towards a TH2 response, as evident by a significant increase in the level of IgG1 by
24 weeks post-vaccination (IgG1 of 8 weeks vs. IgG1 of 24 weeks, p-value:  0.0011).
Although protection elicited by both mutants was still significant when compared to that
of the unvaccinated animals and also the enhanced antibody production, which might
augment the extracellular clearance of Brucella, the protection had decreased from a
maximal level observed at 16 weeks post-vaccination.  However, protection provided by
BA102 was still significantly higher than that stimulated by BA114 at 24 weeks post-
vaccination.  Furthermore, the fact that the former also appears to have an elevated IL-10
response could be explained by the enhanced clearance of the organism by opsonizing
antibody.  Despite an increase in the synthesis of IL-10, the IgG2a-toIgG1 ratio measured
from BA102-vaccinated animals at 24 weeks post-vaccination remains favorable
towards a TH1 response.  Interleukin-10 was once clearly classified as a TH2-associated
cytokine that could down-modulate the TH1 response, and now there is mounting
evidence that IL-10 may act as an inhibitor of the TH2 response both in vivo and in vitro
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(156) (157).  On the contrary, our findings suggest that IL-10 may act as an anti-
inflammatory cytokine to buffer the host system during cellular attack, or that perhaps,
the effect of IL-10 in vitro does not reflect events as they occurred one week after
challenge.
In addition to cytokine profiles, results of lymphocyte proliferation suggest that
Brucella can elicit a long-term memory response regardless of the length of persistence.
Proliferative responses were evident even in lymphocytes from animals at 24 weeks after
inoculating with a short-lived Brucella strain such as BA114.  This is somewhat
surprising when considering the decline in protection observed in response to
vaccination with this mutant long after the bacteria have cleared out of the host.  Taken
together, our findings suggest that the combination of enhanced levels of TH1-type
cytokines (mainly IFN-gamma, IL-2, and IL-12) elicited by BA102 mutant is crucial for
the development and the maintenance of TH1 response in the host, particularly, in a
Brucella-susceptible and non-TH1-driven response host model such as the BALB/c
mouse.  The strongest protection against B. abortus not only requires a finely regulated
balance of cytokines, is more dependent upon the timing of the cytokine response rather
than on the absolute level of cytokine expression.  Finally, our study has demonstrated
that the attenuated B. abortus gcvH mutant, BA102, conferring the greatest cellular
protection against wild type B. abortus without exerting unnecessary side effects such as
splenomegaly on the host, is a good live vaccine candidate.  Future work will be focused
on investigating (1) the vaccine potential of unmarked deletion mutants of Brucella
abortus and Brucella melitensis gcvH genes and virB operons in the natural hosts as well
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as in the pregnant mouse and goat models, and (2) the intracellular trafficking of these
mutants in murine macrophage cell lines and goat trophoblasts.
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CHAPTER IV
THE ISOLATION OF THE GCVH HOMOLOGUE IN BRUCELLA ABORTUS
Overview
A signature-tagged mutagenesis mutant, BA102, carrying a miniTn5-insertion
that resides in the last 40 bp of the gcvH locus in B. abortus was identified as an
attenuated mutant in a mouse model.  The defect in persistence was further supported by
the attenuation in intracellular survival, in which BA102 mutant exhibited decreased
survival within the murine macrophage J774A.1.  The attenuated gcvH mutant of B.
abortus does not require glycine, serine, or threonine supplement for growth in minimal
media.  Nor does it show any in vitro growth defects in liquid media or on plates, when
compared to the wild type B. abortus S2308.  In order to determine whether the in vivo
attenuated phenotype of the gcvH mutant (BA102) can be rescued and restored to that of
the wild type B. abortus S2308, three complement strains were constructed from mutant
BA102, resulting in complemented mutants carrying either the wild type copy of gcvH,
gcvP or gcvHP in tandem on a broad-host range vector pBBR1mcs.  Similar to the
parental mutant strain BA102, all three complemented strains showed normal growth in
liquid and on solid media.  However, only the complemented mutant carrying both wild
type gcvH and gcvP of B. abortus exhibited a small yet significant increase in bacterial
load recovered from the infected macrophages.  Thus, the result suggested that the
intracellular survival defect of the complemented mutant strain carrying both wild type
gcvHP was partially rescued.  Unexpectedly, data from the mixed infection assays of the
parental mutant strain revealed that bacteria of all three complemented strains were not
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recoverable from spleens of animals eight weeks post-inoculation.  The best explanation
for this observation is the addiction module phenomenon, in which the stability of the
plasmid in the host bacterial cells is maintained by the mechanism for killing plasmid-
free bacteria provided by the addiction modules.  The broad-host range pBBR1mcs
vector, which was used as the backbone of all three constructs carrying wild type gcvH,
gcvP, or gcvHP, might have contained a plasmid addiction system and thus the loss of
the plasmid overtime from the complemented mutants resulted in the death of the
bacterium.  Therefore, the complementation of the in vivo attenuation of the BA102
mutant could not be determined.  An alternative approach that involves constructing a
chromosomal integration of wild type B. abortus gcvH and gcvP in an unmarked double
deletional mutant of B. abortus is suggested.
Introduction
Brucella species are Gram-negative a-proteobacteria that reside intracellularly
within their respective hosts.  Brucellae are highly infectious pathogens that cause
abortions and infertility in domestic and wild mammals, and a severe and debilitating
zoonotic disease in humans (31).  Brucella melitensis, Brucella suis, and Brucella
abortus are potential biological warfare agents, and thus, they are a serious concern since
there is presently no human vaccine available (55).  The persistence of brucellae leads to
the chronic phase of brucellosis.  Chronic infection caused by the persistence of bacteria
is a common trait that is also shared by a human pathogen known as the acid-fast
Mycobacterium tuberculosis.  In the chronic infection process, both species are
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endocytosed into host cells where they adapt and survive for extended periods of time
within the acidic membrane-bound compartments (32), (92), (94), (113).  Under in vitro
growth conditions, brucellae require 3-5 days to grow while mycobacteria may take
several weeks before any sign of growth is visible (63), (145), (139).   Thus, the shorter
amount of time required for growth has made Brucella species an ideal model to study
the molecular mechanisms responsible for chronic diseases, which caused by other
pathogens that are genetically difficult to manipulate.
In the previous study, a bank of signature-tagged mutagenesis mutants was
constructed from B. abortus S2308.  Two groups of attenuated mutants were identified
from a mouse model.  One group carries inactivated genes that were necessary for
establishing chronic infections, and the other carries inactivated genes that were essential
for maintaining chronic infections.  A total of fourteen STM mutants were confirmed to
exhibit the in vivo attenuated phenotype.  Four mutants that were unable to establish
chronic infection carried homologues of the type IV secretion system, the purine
biosynthesis pathway, and the O-antigen biosynthesis (69).  The remaining ten
attenuated mutants were defective in the ability to persist.  They carried inactivated
genes that have homologies to those encoding heat shock proteins, membrane-associated
proteins and components of the metabolic pathways in other well-studied organisms
including E. coli, A. tumefaciens, and S. typhimurium (TABLE I).  Among the ten
mutants, the gcvH mutant is of great interest.
In E. coli the gcvH gene resides in the middle of the three-gene operon, which
encodes the multi-subunit glycine cleavage enzyme (GCV) complex.  Numerous studies
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have shown that the GCV complex consisting of GcvT, GcvH, and GcvP subunits, is
involved in the C1 biosynthesis (123).  Others have shown that E. coli cultures at cell
densities of 1.15 g/l and above exhibit an increase in the cleavage activity of the GCV
complex when exogenous glycine was present (64).  In addition, the rise in the uptake of
exogenous glycine correlated with an increase in activity of the glycine transport protein,
CycA permease.  Thus, the gcv operon may be a component of the quorum sensing
system or a quorum sensing-controlled virulence factor (125), (19), (64).  Interestingly,
the glycine dehydrogenase subunit of the GCV complex was found to be one of the three
up-regulated enzymes in tubercle bacillus cultures during non-replicating stages (150),
(149), (151).  Researchers suggested that the glycine dehydrogenase might be involved
in the coupling of the reductive amination of glyoxylate into glycine and the oxidation of
NADH into NAD, which ultimately generates enough ATP to finish the last cycle of
DNA replication before the shutdown of cellular metabolism when oxygen becomes
limited.  Hence it is not surprising that the enzymes encoded by the gcv operon of B.
abortus may serve as cell-associated sensing elements that are involved in modulating
the growth of brucellae within a nutrient-declining environment of the macrophage.
In this study, the in vivo attenuation of the gcvH mutant of B. abortus is further
investigated.  The location of the miniTn5-kanamycin cassette insertion in the mutant is
identified and the arrangement of the gcv operon present in B. abortus is revealed.  The
in vitro growth characteristics of the mutant BA102 are evaluated.  Finally, three
complemented strains carrying the wild type gcvH and/or gcvP are constructed from the
parental mutant BA102 and characterized for the ability to grow under in vitro
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conditions and to survive intracellularly within the macrophage.
Materials and Methods
Bacteria and growth conditions.  Wild-type B. abortus S2308 was obtained from B. L.
Deyoe, National Animal Disease Center, Ames, Iowa.  Strain BA102, an attenuated
mutant derived from the signature-tagged mutagenesis of B. abortus (69), contains a
mini-Tn5(Km) insertion in gcvH of the glycine cleavage system.  Complemented strains,
BA102PCH18.1, BA102PCH19.1, and BA102PCH21.1, were derived from the parental
strain BA102 but harboring a pBBR1mcs-based construct carrying gcvH, gcvP and
gcvHP, respectively.  All plasmid-bearing strains are resistant to both kanamycin and
chloramphenicol.  All bacterial strains used to prepare inoculum for infecting mice were
grown for 3 days at 37°C and 5% CO2 on Brucella agar or Brucella agar-
Chloramphenicol (Cm, 30 mg/ml)-Kanamycin (Km, 50 mg/ml) plates.  For the
macrophage survival assay and the in vitro competitive growth assay, bacteria grown 3
days on plates were used to inoculate 5-ml TSB containing the appropriate antibiotics
and grown for 24 h at 37°C in the rolling drum.  The 24-h liquid culture was then used to
prepare the 48-h culture (a 1:50 dilution of the 24 h culture).  The 48-h culture was
resuspended in PBS (pH 7.4) and adjusted to a concentration of 5X109 CFU/ml (for the
macrophage survival assay) and 1X109 CFU/ml (for the in vitro competitive growth
assay).  For the lZAPIIS2308 library screen, overnight cultures of XL-1 Blue (recA1
endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F’proABlacIqZdDM15Tn10(Tetr)])
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and SOLR (e14- (m c rA -) D ( mcrCB-hsdSMR-mrr)171 s b c C recB r e cJ u v rC
umuC::Tn5(Kanr) lac gyrA96 relA1 lr[F’proABlacIqZDM15]Su-(non-suppressing)) E.
coli strains (Stratagene, La Jolla, CA) were grown at 37 °C in NZCYM broth (10 g NZ
Amine A (casein hydrolysate), 5 g NaCl, 2 g MgCl26H2O, 5 ml 20% Casamino acids,
pH 7.5) containing 0.2% (w/v) maltose.
Cell line.  Macrophage-like cell line J774A.1 was obtained from ATCC (Manassas,VA)
and maintained as frozen cultures in DMEM (Sigma, high glucose (4.5 g/L), 25 mM
HEPES, without L-glutamine) containing 1% non-essential amino acids, 7.3 mM L-
glutamine, 10% DMSO, and 50% fetal bovine serum at –180°C.
Inverse PCR.  Genomic DNA of the mutant was digested with RsaI at 37°C for 3h,
followed by Southern analysis using the kanamycin cassette of the miniTn5 as probe.
Gel slicing corresponding to bands resulted from the Southern analysis were extracted to
purify DNA fragments.  Self-ligation reaction was performed at 14°C overnight,
followed by transformation of E. coli DH5a (F- f80 D lacZ DM15 D[lacZYA-argF]
U169 endA1 recA1 hsdR17(rk
-mk
+) deoR thi-1 phoA supE44 l- gyrA96 relA1).  Colony
PCR was performed using inverse PCR primers, Sign-10 and Sign-11.  Sign-10 primer
(5’GCCGAACTTGTGTATAAGAGTCAG3’) is complementary to the sequence of the
O-end of the miniTn5 cassette and Sign-11 (5’AAAGGTAGCGTTGCCAATG3’) is
complementary to the sequence of the unique RsaI site that resides in the middle of the
cassette.  The inverse PCR product was sequenced and the nucleotide data was searched
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for homology via blastn.  The inverse PCR product was also used as template DNA and
along with Sign-10 and Sign-11 primers generating a “hot” probe to identify clones of
the lZAPIIS2308 library.
Isolation and sequencing of the gcv operon of B. abortus.  The first step involved
screening l phages carrying the gcv operon of B. abortus.  Frozen stock of the
lZAPIIS2308 library was thawed on ice and 10-fold serial dilutions of the frozen phage
stock (1011 PFU/ml) were performed in SM buffer (100 mM NaCl, 10 mM MgSO47H2O,
50 mM Tris-HCl (pH 7.5), 0.01% (w/v) Difco gelatin).  Overnight E. coli XL-1 Blue
culture was harvested by centrifugation for 10 min at 25°C, 4000 X g and resuspended in
sterile 10 mM MgSO4 to obtain a concentration of 1.6X10
9 CFU/ml.  The cell
suspension was incubated at 37°C for 1 h with moderate agitation.  Each serial dilution
of l phage was mixed with the E. coli cell suspension in a 1:2 volume ratio.  The phage-
bacteria mixture was incubated at 25°C for 30 min allowing the bacteriophage to adsorb
to the bacteria.  Molten (47 °C) top agar (0.7% Bacto-agar in NZCYM broth) was added
and immediately poured onto a NZCYM-agar plate.  The top agar was allowed to
solidify at 25°C and then incubated at 37°C for 12-16 h (plaques began to appear after
about 7 h of incubation).  When plaques were about 1-1.5 mm (pinhead) in diameter,
plates were removed from the incubator and refrigerated at least 1 h.  A positively
charged nylon filter circle (Amersham Hybond-N+) was placed on top of the chilled top
agar until it was completely wet.  An 18-gauge needle dipped in India ink was used to
mark filter and underlying agar before lifting it off with a blunt-ended forceps.  The
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membrane filter was soaked in the denaturing solution (1.5 M NaCl, 0.5 M NaOH) for
30-60 sec and the neutralizing solution (1.5 M NaCl, 0.5 M Tris-HCl) for 5 min.  The
filter was rinsed in 2X SSC buffer (0.3 M NaCl, 0.03 M trisodium citrate, pH 7.0), and
blotted dry on Whatman 3MM paper.  Hybridization was performed using 32P-labeled
probe generated from the inverse PCR product prepared as described.  Positive plaques
were identified by aligning the resulting signals on the x-ray film with the original plate.
Agar plugs were removed using a Pasteur pipette and placed in a microcentrifuge tube
containing 500 ml of SM buffer and a drop of chloroform.  The recovered phage in
suspension was re-plated and re-screened until 100% of the phage hybridized with the
hybridization probe.  Then SM buffer containing 0.04% (v/v) chloroform was added to
the plate and incubated overnight at 4°C (the phage suspensions are stable up to one year
at 4°C).  The second step involved the in vivo excision of the pBluescript phagemid from
the lZAPS2308 library.  Each overnight culture of E. coli, XL-1 Blue and SOLR strains,
was used to inoculate fresh LB broth in a 1:100 volume.  E. coli XL-1 Blue culture was
incubated at 37°C for 2-3 h to mid log phase (OD600=0.2-0.5).  E. coli SOLR culture was
grown to an OD600=0.5-1.0 and then chilled to room temperature.  Log-phase culture of
XL-1 Blue cells were resuspended in 10 mM MgSO4 to OD600=1.0 (for single-clone
excision).  A mixture containing the XL-1 Blue suspension (108 CFU), the ExAssist
helper phage (109 PFU), and the amplified phage stock (107 PFU) were incubated at
37°C for 15 min before adding LB broth and further incubating at 37°C for 2-2.5 h with
shaking.  The mixture was incubated at 70°C for 15 min and centrifuged at 4000 X g for
15 min.  The supernatant containing the excised pBluescript phagemid was added to
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freshly grown SOLR cells (OD600=1.0) at 1:2 and 1:20 volume ratios (excised
phagemid:SOLR) and incubated at 37°C for 15 min before adding LB broth.  Incubation
at 37°C was continued for 45 min before 200 ml of the phagemid-SOLR culture was
plated on LB plates containing ampicillin (100 mg/ml), and plates were incubated
overnight at 37°C.  Colonies were restreaked on a fresh ampicillin-containing LB plate
and incubated overnight at 37°C.  Bacterial glycerol stocks containing 20% glycerol
were stored at –80°C.  Plasmid DNA purification was performed (QIAGEN miniprep
kit).  The sequence of the insert, which contains DNA fragment of B. abortus S2308,
was obtained via sequencing using the reverse primer and the T7 primer.
Construction of plasmid-bearing complemented strains from the parental mutant
strain BA102.  For the preparation of complemented strains, three sets of primers were
employed.  Primer set 3 (5’CTCGAGCGGATTGGGTTATGGGAGTTTC3’and
5’CTGCAGAGGGTATTCAAATGTGCGGTATC3’) were designed to amplify the 334
bp putative promoter region of the gcv operon; the 531 bp long DNA fragment including
the open reading frame (ORF) of gcvH (377 bp) was amplified using primer set 4
( 5 ’ C T G C A G C G T C C A C G C A C T T C C C T T 3 ’  a n d
5’TCTAGATCCATGGAAGGAAGGCCG3’); the 2928 bp long DNA fragment
including the ORF of g c v P  (2798 bp) was amplified by primer set 5
( 5 ’ C T G C A G T C G G G T G A T C G A A T G A C C 3 ’  a n d
5’TCTAGAGCATTATCCGACGCATCA3’); and the amplification of both ORFs of
gcvH and gcvP in tandem was achieved by the forward primer of set 4 and the reverse
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primer of set 5, resulting a product of 3327 bp in length.  All PCRs were performed
using High Fidelity Expand Taq Polymerase (Roche).  Reaction amplifying the putative
promoter region of the gcv operon was performed with a host start cycle and followed by
a series of cycles (45 sec at 95°C, 1 min 48 °C, 3 min at 68°C, 10 cycles; 45 sec at 95°C,
1 min at 52°C, 3 min at 68°C, 25 cycles).  Reactions amplifying gcvH, gcvP, and gcvHP
in tandem were also performed with a hot start cycle and followed by a regimen of
cycles (45 sec at 95°C, 1 min at 57°C, 4 min at 66°C, 5 cycles; 45 sec at 95°C, 1 min at
56°C, 4 min at 66°C, 4 cycles; 45 sec at 95°C, 1 min at 55°C, 4 min at 66°C, 3 cycles; 45
sec at 95°C, 1 min at 54°C, 4 min at 66°C, 2 cycles; 45 sec at 95°C, 1 min at 53°C, 4 min
at 66°C, 25 cycles).  All PCR products generated from primer sets as described above
were purified following gel electrophoresis, and subcloned into pCR2.1 resulting as
pPCH10, pPCH11, pPCH12, and pPCH20.  Gel purified XbaI-XhoI fragment from
pPCH10 carrying the putative promoter region of the gcv operon was ligated into the
XbaI-XhoI digested pBBR1mcs resulting as the pPCH17 construct.  Gel purified XhoI-
PstI fragments containing either gcvH, gcvP or both gcvHP in tandem were then ligated
into the XhoI-PstI digested pPCH17 to generate the following plasmids, pPCH18,
pPCH19, and pPCH21, respectively.  Each plasmid was electroporated into the mutant
strain BA102, resulting as three complemented strains BA102PCH18, BA102PCH19,
and BA102PCH21.
In vitro competitive growth assay.  A mixture of 48-hour cultures containing equal
volumes of either wild type S2308 and parental mutant BA102 or wild type S2308 and
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complemented mutant was used to inoculate LB broth in a 1:100 dilution.  The
inoculated media were incubated at 37°C, 250 rpm for 24 h.  Ten-fold serial dilutions
were performed for the 0 and 24 hour time points.  Each dilution was plated on tryptic
soy agar (TSA) plates (non-selective), and kanamycin-containing TSA plates (selecting
for BA102), and kanamycin-and-chloramphenicol-containing TSA plates (selecting for
complemented strains, i.e., BA102PCH18, BA102PCH19, and BA102PCH21).  After
three days of incubation at 37°C, colony counts were recorded.  The results were
tabulated from three independent trials.  The number of CFU on TSA plates represents
the total number of brucellae, whereas that on TSA containing antibiotics represents the
bacterial number of the mutant or complemented strains.  The input ratio is the
inoculated ratio (0 hour time point), which is equal to the bacterial number of the wild
type S2308 divided by that of the parental mutant or complemented mutant.  The output
ratio is the recovery ratio, which is equal to the bacterial number of the wild type S2308
after 24 h incubation divided by that of the mutant or complemented mutant after 24 h
incubation.  The competitive index (CI) represents the output ratio divided by the input
ratio.
Auxanography screening.  Plates were prepared from kanamycin (50 mg/ml)-
containing Brucella minimal media (per liter, pH6.9+0.1, 7.5 g NaCl, 10 g K2PO4, 0.1 g
sodium thiosulfate, 23.8 ml glycerol, 5 g lactic acid, 1.5 g glutamic acid, 42 mM
MgCl26H2O, 0.18 mM FeSO47H2O, 0.19 mM MnCl24H2O, 4 mg/ml thiamine, 4 mg/ml
nicotinic acid, 0.01 mg/ml calcium pantothenate, 15 g Bacto-agar) with the addition of
82
eleven different supplements [Davis, 1980 #9952].  Composition of supplemented media
is described as follows.  Media 1 (5 mM adenosine, 0.1 mM histidine, 0.3 mM
phenylalanine, 5 mM glutamine, 0.32 mM thymine), media 2 (0.3 mM guanosine, 0.3
mM leucine, 0.1 mM tyrosine, 0.32 mM asparagine, 4 mM serine), media 3 (0.3 mM
cysteine, 0.3 mM isoleucine, 0.1 mM tryptophan, 0.1 mM uracil, 5 mM glutamic acid),
media 4 (0.3 mM methionine, 0.3 mM lysine, 0.3 mM threonine, 0.3 mM aspartic acid),
media 5 (0.05 mM thiamine, 0.3 mM valine, 2 mM proline, 0.6 mM arginine, 0.13 mM
glycine), media 6 (5 mM adenosine, 0.3 mM guanosine, 0.3 mM cysteine, 0.3 mM
methionine, 0.05 mM thiamine), media 7 (0.1 mM histidine, 0.3 mM leucine, 0.3 mM
isoleucine, 0.3 mM lysine, 0.3 mM valine), media 8 (0.3 mM phenylalanine, 0.1 mM
tyrosine, 0.1 mM tryptophan, 0.3 mM threonine, 2 mM proline), media 9 (5 mM
glutamine, 0.32 mM asparagine, 0.1 mM uracil, 0.3 mM aspartic acid, 0.6 mM arginine),
media 10 (0.32 mM thymine, 4 mM serine, 5 mM glutamic acid, 0.1 mM
diaminopimelic acid (DAP), 0.13 mM glycine), and media 11 (0.1 mM pyridoxine, 0.1
mM nicotinic acid, 0.1 mM biotin, 0.1 mM pantothenate, 0.47 mM alanine).  Briefly,
strain BA102 was streaked on plates and incubated for 3 days at 37°C, 5% CO2.
Results
Isolation of gcv operon in B. abortus.  Prior to the availability of the Brucella genome
sequences, isolation of gcv operon in B. abortus was achieved as follows.  Several clones
of the lZAPIIS2308 library were identified using 32-P labeled probe synthesized using
inverse PCR products generated as described in Materials and Methods.  Sequencing of
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these clones revealed that the overall gene arrangement of the gcv operon of B. abortus
is similar to that of B. melitensis, in which the operon is comprised of three genes
arranged in the order gcvT-gcvH-gcvP presumably encoding a multi-subunit enzyme
representing the glycine cleavage system (Fig. 11).  In addition, sequencing of the
inverse PCR product confirmed that the insertional site of miniTn5 in BA102 resides in
the last 40 bp of the gcvH gene (Fig. 12A).  As a result, transcription of gcvH was
disrupted and that of gcvP was abolished.
In vitro growth characteristics of complemented mutants.  In order to determine
whether the in vivo defect of BA102 mutant can be rescued and restored to the
phenotype of the wild type B. abortus, three complemented mutants were constructed
using a broad-host range chloramphenicol-based pBBR1.mcs vector.  First, the putative
gcv promoter region and the gcvH and/or gcvP genes were amplified, and subsequently
cloned into the pBBR1.mcs vector.  Then all constructs carry the putative gcv promoter
region along with the gcvH and/or gcvP, generating pPCH18, pPCH19, and pPCH21,
respectively (Figure 12B).  The nucleotide sequences of the inserts were confirmed via
sequencing.  Finally, each construct was introduced into the kanamycin-resistant mutant
strain BA102, resulting in complemented mutants that showed resistance to both
kanamycin and chloramphenicol antibiotics.  These three derivatives of B. abortus
BA102 are known as BA102PCH18(g c v H), BA102PCH19(g c v P ), and
BA102PCH21(gcvHP).
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584281 gcgtgaaatc gtcgattaga gacaataatt ccgcatgact tgtgcgccgg attgggttat
584341 gggagtttcg ttgggtgtcg gggcgtcata tcgtgtggtg ttcttgcact gtctgtttgc
584401 gggagagagc cgttaaggcc gccgaagggg aaaacgcccg aaatctctca ggtacaagga
584461 accgcaggcg ggtaagacaa ctctggaaag tcgggggcaa ctccgcgccg aaggtgtaag
584521 tatggcttta tatatagcca tgcgagtctc tcaggcctga gacagagggg cacgaaccaa
584581 ccgcattttg cggaaggcat acgtgcgtct ctggagttgt tatgggcgat accgcacatt
584641 tgaataccct gccgttgcag gatctgcatg aaaaggctgg cgcgcgcttc ggcggctttg
584701 ccggctggaa catgccaacc acctatccgc tgggtgtgat gaaggaacat cttcatacgc
584761 gcgaccatgc gggcctcttc gacatttccc acatgaagct ggtggaagtt tccggcgcgg
584821 atgccgccgc gcttctcgcc gagacctgcc cgctcgatcc gacgatcctg aagacgggcc
584881 agtcgaaata tacgttcttc ctcaatgata atggcggcgt gctggatgat ctcatcgtca
584941 cgcgccttgg cgaagaccgt ttcatggttg ttgccaatgc gggcaatgcc gatgccgaca
585001 tcgagcatct caatgaagcc gcgtcgggca aggccgtaaa ggttaatccg ctcgaccgtg
585061 ttttccttgc tttgcagggg ccggaagcag aagctgtcat caccgatgcc ggtctgccgg
585121 gcgccgatct tgccttcatg agcggtttcg agccgaaaca gagctggttc atgacccgtt
585181 cgggctatac cggcgaagac ggtttcgaga ttggcctgcc tgccgatgaa gcccgtgcgc
585241 tggccgaaaa gcttcttgcc gatgaacgtg tcgaatggat cggccttgcc gcccgcgatt
585301 ccttacgcct cgaagcgggc ctctgcctgc acggtcagga catcacgccg gaaaccgatc
585361 cggtttcggc tggcctcacc tgggcgatca ccaaggctgt gcgcgaaaaa gccgccttca
585421 acggcgcgaa agccgttctc gacgccattg ccaaaggcgc cagcgccaag cgcgtcggcc
585481 tcaagccgga aggccgccag ccggtgcgcg ccggggccga ccttttcgac gaaagtggcc
585541 gccagatcgg caccgtcacc tcgggcggct ttggcccttc cgccggtttc ccggtcgcca
585601 tgggctatgt cgaggcaagc ctcgccaccc ccggcacccg tgtttttgca gatgttcgcg
585661 gcaacaaggt tcccgttgac gtccacgcac ttcccttcac accgcatcgc tatcgcaaag
585721 gatgatttcc atggccaata tcctgttcac cgaagatcat gagtggatca acgtcgaaaa
585781 cggcgttgcc acggttggca tcacgatcca cgcacaggaa cagctcggcg acctcgtttt
585841 cgtcgaattg ccggaagtgg gccgcaccgt tgccaagggc gatggcgtgg tggttgtgga
585901 gtcggtcaag gccgcttccg acgtctacgc gccggtcgat ggcgaagtgg tggaagtcaa
585961 cgatgctgtc gcgagcgatc cttcccttat caatcaggct gccgaaggcg aaggctggct
586021 gttcaagctg aagcttgccg atgaaggcCA gctcacgggc ctgctcgaca aggccggtta
586081 tgaaaagctg atcgggtgat cgaatgaccg aatttcttcc ctttgtggcc cgccatatcg
586141 ggccgagaca tgaagacgag cgcgccatgc tggcagcgct cggccttcct tccatggaaa
586201 ccctcataac gcaggcggtt ccggcctcca ttcgcctcaa ccgcgcgctg aacctgccag
586261 cggcgctcag cgaagcggac gcacttgcgg aactgggcac gatcatgggc cgcaacgtgg
586321 tgaagaagag cttcatcggc gcgggctatc acggtgttca cacgccgccg gtcatccagc
586381 gcaacctgtt tgaaaacccg gcctggtaca cggcttatac gccctaccag tcggaaatca
586441 gccagggccg ccttgagctt ctgttccact tccagacact ggttgccgaa ctgaccggcc
586501 tgccggttgc ctgtgcctcg ctgctcgacg aggcgactgc cgttgccgaa gccatcggcg
Fig. 11.  Position of the gcv operon of Brucella melitensis on chromosome II (584281-
588960).  Sequencing results of the inverse PCR product confirmed that gene
arrangement of the gcv operon in B. abortus is similar to that of B. melitensis and also
revealed the location of the mini-Tn5 kanamycin cassette insertion in B. abortus mutant
strain BA102, residing at the position comparable to position 586049 of B. melitensis
chromosome II as shown.  gcvT (584622-585725), gcvH (585722-586099), and gcvP
(586104-588902), the start codon of each is underlined.  The putative promoter region of
the gcv operon, which has been amplified and cloned into pPCH18, pPCH19, and
pPCH21, is showing in red (584327-584621).
Mini-Tn5 Km cassette insertion
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586561 ttgcctgccg ccatcatcgc gacaagcgca gccgcattct gcttgctggc gaactgcatc
586621 cgcagacggt cgatgtggtg aacacccgcg ctgaaccgct cggctgggag atcgccaccg
586681 gcagcgatgt tgacgacaac accgccgcaa tcgtggttcc atggccggat acgcgcggcg
586741 tctatggcga ttttgccaag gtcattgccg atgccaaggc caagggcgcg ctggttatcg
586801 ccgttgccga tccgctggcg ctcaccatca tggaagcgcc tgccaggtgg ggcgcggaca
586861 tggccgtcgg ctccatgcag cgctatggcg tgccgatggg ctttggcggc ccgcacgcgg
586921 cttatcttgc agtgtccgag gcgctcactc gcattattcc gggccgcatc gtcggccagt
586981 cggtcgatgc gcatggccgc gcggcctatc gtctggcgct ccagacccgc gagcagcaca
587041 tccgccgcga caaggcgacc tccaatatct gcaccgcgca ggcgcttctg gccaacatgg
587101 ccgcagcttt cgccatctgg catggcccgg ctggcttgca ggcgattgca acgcgcgtgg
587161 ccgctctggc cgcccgtttt gctgccgcgc tcaaggctgc cggtgttgaa attgcgggcg
587221 aaagcctgtt cgatacggta acggccaagg ttccgggcaa agccgcggca atcgcagccg
587281 aagccgacaa gggcggccgc ctgatccgca tcatcgatgc ggatacggtc ggcgtcactt
587341 tcgacgaaac ctcgacggaa gaggatctga cggccctggc atcgctcttc ggtgcgaagc
587401 tggttggcgg cgacacagtt cttgttccgg gcaaggaacg cggggaaggt ttcctcacgc
587461 aggaagtatt ccattcacat cgttccgaaa ccgagatgat gcgcttcctg cgtcgtctgg
587521 ccgacaagga tctggcgctc gaccgcgcga tgatcccgct tggttcctgc acgatgaagc
587581 tcaatgcggc ggcagaaatg atgccggtga gctggaatac ggttgcaaac ctgcatcctt
587641 ttgcgcctgc cgagcaggtg cagggttatg cgaaaatgac gtccgatctg gaagcatggc
587701 tttgcgaaat caccggtttt gcgggcgttt cattgcagcc aaatgccggt agtcagggtg
587761 aatatgccgg ccttatggcc atccgccact atcatcaggc gcgggggcag ggccatcgca
587821 acatctgcct tatcccgtcc tcggcgcatg gcaccaatcc ggccagcgcc tccatggcgg
587881 gcatgagcgt cgtcgtcgtc aattgccgcc cggatggcga catcgatatt gatgatctca
587941 aggccaaggc ggaaaagcat cgcgataatc tcgccgcctt catgattacc tatccgtcca
588001 cctatggcgt gttcgaggaa ggcatcaaag ccttctgcga gattgtgcat gacaatggcg
588061 gccaggtcta tttcgacggc gcgaacctca atgcgcttgt cggtctggcg cggcctgccg
588121 atatcggcgc ggacgtctgc cacatgaatc tgcacaagac cttctgcatc ccgcatggcg
588181 gcggtggtcc gggtgttggc ccgattggcg tggcgaaaca tctggtgcct tatctgccgg
588241 gccatgtgga agccggttcc gaacacgctg ttgccgcagc gcagttcggc agcgcatcca
588301 ttctggtcat tacgtggatg tatatccgca tgatgggcgg ggccggtttg aagaaggcga
588361 cggaagctgc aatcctcaat gccaattata ttgcgcatcg tctgaagggt gtttacccga
588421 tcctttatac cggcgcgcat gaccgcgtgg cgcatgaatg catcgtggat acgcgcgtat
588481 tgaaggacag tgcgggcatt accgtggaag acgtggccaa gcgcctgatc gactatggtt
588541 tccatgcgcc gaccatgtca tggccggttg ccggaacgct gatgatcgag ccgaccgagt
588601 ccgagcccaa gctggagatc gaccgtcttt gcgatgcgat gatcgcgatt gcaggcgagg
588661 cgaagaaggt tgccgatggc gtctggcctg cggatgacaa tccgcttgcc aatgcgccgc
588721 atacggcgag cgatacgctg gcaacggaat ggaagcatcc ctatacccgt gaggaagccg
588781 tattccccgg cggtgctttc gatccgacgg caaaatattg gccgccggtc agccgcgtgg
588841 ataatgtcgg cggcgaccgg aacctcatct gctcctgccc gcctgtcgca gcctatggct
588901 gacaggcgcg gctggagcat tttcgcacca aaagtgtgaa acgcctaagc ggggaaatca
Fig. 11 continued.
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Fig. 12.  Glycine cleavage system of B. abortus.  (A)the gcv operon of B. abortus S2308
and the position of the mini-Tn5 kanamycin cassette insertion, (B)the pBBR1.mcs-based
constructs carrying the putative gcv promoter region and the gcvH and/or gcvP of B.
abortus generating pPCH18, pPCH19, and pPCH21, respectively.
B
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The parental mutant strain BA102 exhibited no apparent in vitro growth defect
when grown in rich media, such as tryptic soy broth (TSB).  In an attempt to characterize
the mutant more fully, growth was examined using Brucella minimal medium
supplemented with glycine and/or serine.   Neither the mutant BA102 nor any of the
plasmid bearing strains exhibited any growth defects under the conditions used (Data not
shown).  This observation is similar to that of E. coli gcv mutant, in which the gcv
mutant showed no requirement of any amino acid supplements for growth.  On the
contrary, the serA/gcv double mutant of E. coli required both glycine and serine
supplements in the minimal growth media (130).  When grown on plates, all strains
including the parental mutant BA102 showed no changes in colony size.  Thus, these
results indicate that all three constructs are steadily maintained under in vitro conditions.
Intracellular survival of plasmid-bearing strains in the macrophages.  The ability of
each complemented strain to survive intracellularly in macrophages was compared to
that of the parental mutant strain BA102 along with the short-lived in vivo virB10
mutant, BA114 (Fig. 13).  Complemented mutant harboring a wild type copy of B.
abortus gcvH, showed no significant differences in the ability to survive within the
macrophages when compared to that of the parental strain.  On the other hand, mutant
strain carrying a wild type B. abortus gcvP exhibited a continuous decrease in bacterial
load 24 h post-infection of macrophages, although the reduction was not as severe as that
of BA114.  The complemented strain carrying both gcvH & gcvP showed a slight
increase in numbers after the initial reduction, i.e, from 24 h to 48 h post-infection of
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Fig. 13.  Intracellular survival of B. abortus complemented mutant strains in the murine
macrophage J774A.1.  The graph is showing the average recovered bacterial load at t=24
and 48 h post-infection in relative to that at t=0.  S2308, virulent B. abortus; BA102,
parental gcvH mutant; BA114, virB10 mutant; BA102PCH18, complemented mutant
carrying gcvH; BA102PCH19, complemented mutant carrying gcvP; BA102PCH21,
complemented mutant carrying gcvHP.
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macrophages.  Compared to the recovery of the wild type S2308, the recovery of the
complemented strain carrying gcvHP was small (t=24, 1.98X105; t=48, 3.1X105
CFU/mL), yet it was significant (p-value=0.0163) (Fig. 13).
In vivo survival of complemented strains.  The parental mutant strain BA102 exhibited
an attenuated phenotype in the mouse model as the result of an insertional mutation in
the 3’ end of the second gene of the gcv operon in B. abortus.  In order to determine
whether the absence of a fully expressed gcv operon is responsible for the observed
phenotype, BA102 was complemented with each of the three plasmids described earlier
and the virulence/survival of each complemented strain was evaluated in competitive
infection assays with the parental mutant BA102.  Groups of 5 mice were inoculated
with the mixture of complemented mutant and parental mutant BA102 (1:1 ratio) and
sacrificed at eight weeks post-inoculation.  Animals of the control group were inoculated
with a mixture of mutant BA102 and wild type S2308 B. abortus and also sacrificed at
the specified time.  Bacteria were harvested from spleens on kanamycin-containing TSA
plates as well as kanamycin/chloramphenicol-containing TSA plates.  Unexpectedly,
bacterial growth was only observed on kanamycin-containing TSA plates from spleens
of mice inoculated with a mixture of complemented strain and mutant BA102, and those
inoculated with a mixture of mutant BA102 and wild type S2308.  Chloramphenicol-
resistant colonies were not recovered from the spleens of those inoculated with the
mixtures containing individual complemented strains bearing any of the recombinant
plasmids, suggesting that only bacteria of the parental mutant strain BA102 were
90
recovered from spleens of animals inoculated with the complemented mutant-containing
mixture.
Discussion
Similar to the glycine cleavage system (gcv) operon of B. melitensis, the B.
abortus gcv operon consists of three genes arranged in the following order, gcvT-gcvH-
gcvP. The insertion of the miniTn5-cassette into the gcvH of B. abortus, resulted a
mutant strain exhibiting an attenuated phenotype in the mouse model.  This gcvH
mutant, designated strain BA102, persisted up to 24 weeks post-inoculation in the host.
The mutant was exhibited reduced survival within macrophages, although the
intracellular killing occurred at a much slower rate than that of the short-lived virB10
mutant (BA114) (69).  Sequence analysis revealed that the miniTn5 kanamycin cassette
was inserted within the last 40 bp of gcvH, and thus the disruption of the gcvH may also
abolish the expression of the gcvP.
In E. coli, the glycine cleavage complex plays an important role in the
biosynthesis of glycine and C1 units.  During growth on glucose containing minimal
medium, as much as 15% of the assimilated carbon in E. coli has been estimated to
provide serine, glycine, and C1 units via the serine-glycine interconversion pathway
(117).  The needs for glycine and one-carbon units are balanced by the action of the
glycine cleavage system.  The glycine cleavage enzyme complex (GCV) catalyzes the
conversion of glycine into a C1 unit and together with the serine hydroxymethyl
transferase (glyA gene product) interconverts glycine and serine (Fig. 14).  Serine and
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The serine-glycine interconversion pathway
Fig. 14.  The serine-glycine interconversion pathway in E. coli (117).  The needs for
glycine and one-carbon units are balanced by the action of the glycine cleavage system.
The glycine cleavage enzyme complex (GCV) catalyzes the conversion of glycine into
5,10-mTHF, an important contributor of C1 unit in cell metabolism, and together with
the serine hydroxymethyltransferase (GlyA) interconverts glycine and serine.  5,10-
mTHF, N5, N10-methylenetetrahydrofolate; open box, generated product; shaded box,
enzyme involved in the reaction.
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glycine are also derived from the alternate pathway known as the threonine utilization
cycle (Fig. 15). In this pathway, threonine is converted to glycine through the catalytic
reactions of threonine dehydrogenase (tdh gene product) and a-amino-b-ketobutyrate
lyase (kbl gene product), and in turn, glycine is then converted to serine by the catalytic
reaction of GlyA (56), (10).  E. coli and S. typhimurium mutants carrying single
mutations in ser genes (serA, serC, & serB) of the serine biosynthesis pathway required
either serine or glycine supplement for growth while those carrying a mutation in glyA
gene exhibited growth on glycine-supplemented minimal media (109), (130).  However,
all serine and glycine auxotrophs of E. coli and S. typhimurium have been shown to grow
slowly in serine-and glycine-free minimal media provided that threonine was present
(144).  On the other hand, double mutants carrying a mutation in one of the known ser
genes plus a mutation in glyA, gcv, or tdh did not exhibit growth on minimal medium
supplemented with threonine (115).  Taken together, it is not so surprising that the
BA102 mutant resulted from a single insertional mutation in the gcv operon of B.
abortus has no observed in vitro growth phenotype.
BA102 carrying a single insertional mutation in the gcvH gene exhibited normal
growth on unsupplemented Brucella minimal media, suggesting that the GCV systems
of B. abortus and E. coli may share a similar function.  Ghrist and colleagues (59)
showed that in E. coli the glycine transport system, CycA permease, regulates the gcv
operon by transporting glycine into the cell, which in turn induces gcv expression
endogenously.  Interestingly, Han and colleagues (64) have reported evidence for cell-
density-dependent glycine degradation in E. coli.  In the presence of exogenous glycine,
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The threonine utilization pathway
Fig. 15.  Formation of glycine and serine from threonine in E. coli (56), (10).  5,10-
mTHF, N5, N10-methylenetetrahydrofolate; open box, generated product; shaded box,
enzyme involved in the reaction.
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E. coli cells at cell densities below 1.15 g/l exhibited a repression on the biosynthesis of
serine and glycine.  Conversely, at cell densities above 1.15 g/l, the degradation of
glycine was associated with an increased uptake rate of exogenous glycine, cleavage
activity by GCV, and degradation of both glycine-derived serine, and glucose-derived
serine to pyruvate.  Taken together, it has been suggested that the switch in metabolism
might be regulated by population-density dependence of quorum-sensing systems, i.e., at
high densities, quorum sensing up-regulates the cycA expression allowing more glycine
to be transported into the cell and hence up-modulating the cleavage activity of the
glycine cleavage system in processing glycine into serine and C1 units.
Quorum sensing (QS) allows bacteria to detect the density of their own species
and alter their metabolism to take advantage of the density (19).  Bacterial
communication via quorum sensing is also important in the production of virulence
factors, antibiotic resistance, and biofilm development.  In P. aeruginosa, quorum
sensing has been shown to regulate the production of virulence factors including
proteases, exotoxin A, rhamnolipids, and pyocyanin, to induce inflammation, and to be
involved in biofilm formation and development (37), (128), (114), (35).  In addition, it
has been implicated in antibiotic resistance (38).  Other studies involved the use of
models for both acute and chronic infection have further supported that the quorum
sensing systems of P. aeruginosa contribute to its pathogenesis by enabling the bacteria
to initiate infection and to persist in a host (122), (140).  The bacterial cell-to-cell
communication enables a bacterial population to mount unified response that is
advantageous to its survival by improving access to complex nutrients or environment
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niches and collective defense against other competitive microorganisms or eukaryotic
host defense mechanisms, thus becoming better adapted to combating environmental
threats.  In this case, it is possible that brucellae rely on cell-to-cell communication for
the successful adaptation to their intracellular habitat.  Given these findings, the presence
of this in vivo attenuated BA102 suggests that the gcv operon may be a component of the
QS system or a QS-controlled virulence factor.
Another interesting phenomenon, which involves the gcv operon, has been
observed in Mycobacterium tuberculosis.  The glycine dehydrogenase encoded by gcvP
of M. tuberculosis, has been identified as one of the three up-regulated enzymes found in
a tubercle bacilli culture grown in a slow-stirred in vitro model, simulating an oxygen-
depleted environment found in necrotic lung tissues of infected patients (150).  Thus, it
has been suggested that glycine dehydrogenase is involved in the coupling of the
reductive amination of glyoxylate into glycine and the oxidation of NADH into NAD, in
which this coupling reaction serves mainly to provide enough ATP to finish the last
cycle of bacillary replication before oxygen limitation stops growth completely.  This
orderly shutdown is essential to continue the survival of M. tuberculosis in a quiescent
form.  Furthermore, the activity of the glyoxylate pathway, which bypasses the
tricarboxylic acid cycle (TCA), has been shown to come into prominence during survival
of mycobacteria under oxygen limitations (76), (15).  Since both Brucella and TB are
chronic disease-causing agents, it is possible that both pathogens utilize the enzymes
encoded by the gcv operon for a similar purpose.
In order to complement the defect caused by the insertional mutation in gcvH of
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B. abortus, three pBBR1mcs-based constructs carrying the wild type copies of gcvH
and/or gcvP along with the putative gcv promoter were introduced into the mutant strain
BA102, generating three complemented strains of BA102 (Figure 2B).  All three strains
have no in vitro growth defects.  Complemented mutant strain carrying the gcvH showed
a similar reduction of intracellular survival as the parental mutant strain BA102.
However, the mutant strain harboring both wild type copies of gcvH and gcvP, exhibited
a small yet significant recovery in bacterial load after the initial killing (Fig. 3),
suggesting that the defect in survival within the macrophage was partially rescued.
Interestingly, the presence of the wild type gcvP alone did not rescue the mutant strain
from the macrophagic killing.  Instead, the reduction in bacterial load of complemented
mutant strain carrying gcvP was similar as to that of BA114.  This result suggests that
although the activity of glycine dehydrogenase encoded by the gcvP gene was restored,
the GCV system remained incomplete without a functional GcvH enzyme.  Thus, an
excess of the partially processed product generated by the GcvP may have caused a
disruption of metabolic balance in the bacterial cell and ultimately led to the death of the
organism within the macrophage.
To further determine whether the attenuated phenotype of BA102 in vivo can be
rescued and restored to the wild type phenotype of B. abortus S2308, all three plasmid-
bearing strains were compared for their persistence in a mouse infection model.
Unfortunately, bacteria of all three complemented strains were not recoverable after a
mixed infection with the parental mutant BA102.  One possible explanation is the
existence of the addiction module in the pBBR1mcs vector, which may be similar to that
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of the par locus of plasmid RK2/RP4 (47), which results in cell death to the plasmid-free
progeny upon the loss of the pBBR1mcs-based construct.   An alternative approach to
resolve the instability of the plasmid is to construct an unmarked deletional mutant
carrying a chromosomal copy of the gene of interest, so that the complementation is the
result of gene expression from a single copy of the gene.  In this case, a suicide vector-
based construct carrying both wild type copies, gcvH and gcvP , along with a
promoterless reporter gene is introduced via a single event of homologous recombination
into the chromosome of an unmarked double (gcvH-and-gcvP) deletional mutant.  The
endogenous gcv promoter, thus, regulates the expression of these inserted genes.  The
expression level of gcv operon can then be monitored by that of the reporter gene under
in vitro or in vivo conditions.
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CHAPTER V
CONCLUSION
The genetic basis for the persistence of Brucella in the host remains poorly
understood.   In this manuscript, we identified genes of B. abortus required for chronic
infections in the BALB/c mouse model.  The approach employed signature-tagged
transposon mutagenesis (STM) that permitted the screening of multiple mutants in a
single passage and simplified the identification of the interrupted genes.  The STM
screen identified 27 mutants putatively attenuated for chronic infection.  A statistically
significant competitive-infection defect was confirmed in 14 of these mutants.  Thus, the
statistical significant evidence for attenuation was obtained for 8% of the mutants
screened (14 of 178).  Assuming that the mutagenesis was random and that the coding
density of the 3200-kb B. abortus genome is similar to that of E. coli, our data suggest
that as much as 257 genes may be involved in establishing and maintaining chronic
infection in mice after intraperitoneal (i.p.) injection.  In contrast, the STM screen of S.
typhimurium in mice via i.p. injection revealed that only 3% of its 4400-kb genome is
required for acute infection (66).  The greater number of virulence genes required for
chronic infection versus acute infection may reflect the requirements for additional
adaptations to ensure long-term persistence, such as those that prevent clearance of B.
abortus from the host immune system.
Our hypothesis of the study was that B. abortus possesses one group of virulence
factors for establishing the initial infection, which is characterized by rapid bacterial
growth, and another group that contributes to establishing and maintaining chronic
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intracellular infection, in which little or no growth is observed (8), (14).  Indeed, the 14
attenuated mutants fell into two groups.  Four mutants were unable to establish the
infection by either 2 or 8 weeks post-infection.  The 10 remaining mutants were able to
establish the infection at 2 weeks post-infection but failed to sustain chronic persistence
at 8 weeks post-infection.  The first group included mutants with transposon insertions in
genes required for the O-antigen biosynthesis (BA184 mutant), the biosynthesis of
aromatic amino acids (BA100 mutant), and the type IV secretion system (BA41 and
BA114 mutants).  Genes inactivated in these mutants are predicted to be involved early
during infection. For example, BA184 (wbkA mutant) was highly attenuated and
outcompeted by wild type S2308 by a 1000-fold at 2 weeks post-inoculation, suggesting
that the mutant was eliminated early in the infection.  This is expected since rought
mutants are sensitive to complement-mediated killing mechanisms and thus may reach
the spleen only in small numbers (1), (30), (43).  The transposon-insertion in BA100
renders the mutant defective in the biosynthesis of aromatic amino acids as determined
by auxanography.  This biosynthesis pathway is also involved in the biosynthesis of 2,3-
dihydroxybenzoic acid, the only siderophore known to be produced by Brucella (90).
However, the siderophore was showed to be dispensable for the growth in mice (11).
Thus, it is more likely that the attenuation of BA100 is the result of its inability to
acquire aromatic amino acids in the host.  Two mutants (BA41 and BA114) carrying
transposon-insertion in the putative type IV secretion system in B. abortus, encoded by
the virB genes, were also defective for initiation of chronic infection. Mutant BA114
(virB10) showed a higher competitive colonization defect than mutant BA41 (virB1).  A
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similar effect has been observed in Agrobacterium tumefaciens, a plant pathogen that is
closely related to Brucella.  Mutant of A. tumefaciens with inactivated virB1 exhibited a
lower degree of attenuation than the one with a mutation in virB10 (12).  In B. suis, virB
mutants were unable to multiply in HeLa cells or macrophage cell line in vitro (103).
Therefore, these data together with our findings that virB1 and virB10 mutants of B.
abortus were unable to persist in mice after i.p. infection suggest that the attenuation of
survival in the mouse model is the result of the inability of these mutants to grow
intracellularly.
The second group of mutants that were unable to maintain chronic infection
included mutants with inactivated genes involved in the glycine cleavage system
(BA102 mutant), the production of glutamate synthase (BA152 mutant), the nutrient
uptake (BA159 mutant), and several unknown functions (BA31, BA38, BA63, BA73,
and BA122 mutants).  As the first complete genome sequence of Brucella species
became available, some of these unknown functions were inferred as glutamate
decarboxylase beta (BA31), histidinol phosphate aminotransferase (BA38), glycine
betaine (BA63), and a heat shock protein (BA122).  Although the inactivation of genes
in these mutants did not show an effect in the initiation of chronic infection, these genes
were required for chronic persistence of the organism.  Mutant BA102 carried a
transposon insertion in a gene region showing homology to gcvB encoding glycine
dehydrogenase in Mycobacterium tuberculosis.  The activity of glycine dehydrogenase
showed a 10-fold increase in tubercle bacillus cultures during non-replicating stages
(150).  Our finding that glycine dehydrogenase is required for the survival of B. abortus
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in the mouse spleen suggests that both Brucella and Mycobacteria may share similar
metabolic pathways for chronic persistence in the host.  This result underlines the
importance of research on the host-pathogen interactions of B. abortus in elucidating the
molecular mechanisms of intracellular persistence, which may be shared by other
chronic intracellular pathogens.
The presence of the two defined groups of attenuated mutants suggests that B.
abortus uses distinct sets of virulence determinants for the initial establishment and the
maintenance of chronic infection.  Long-term survival of the organism in the host is the
undesirable feature of the disease, yet the persistent nature of Brucella may be a great
attribute for developing longer lasting live vaccines.  To be effective, live attenuated
vaccines must persist long enough to elicit protective immunity, yet they should be
cleared as quickly as possible to avoid unnecessary side effects.  Attenuated mutants
with similar genetic background and possessed different survival characteristics are ideal
for studying the vaccine potential with regard to the persistence of the strain.
B. abortus gcvH mutant, persisted up to 24 weeks post-infection in mice, showed
a moderate attenuation for growth in macrophages while B. abortus virB10 mutant,
cleared out as early as 8 weeks post-infection, exhibited a more marked defect in the
intracellular survival.  This observation of virB10 mutant is in agreement with several
studies of type IV secretion system (T4SS) in Brucella, in which the virB operon play a
critical role in the intracellular multiplication and virulence (79), (127).  The T4SS of B.
abortus is required for modulation of the intracellular trafficking with HeLa cells (29)
but not evasion of nitrosative or oxidative bactericidal killing by macrophages (136).
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Inactivation of the gcv operon, on the other hand, is expected to prevent adaptation to
low oxygen environments.  Consistent with the anaerobic state of Brucella is the
observed requirement for cytochrome bd oxidase during intracellular growth (46).
Under the conditions of depleting oxygen found in inflammatory and necrotic tissues,
glycine dehydrogenase may serve to generate NAD from a reduced form, which
provides ATP to support the completion of a final cycle of DNA synthesis before the
shutdown of replication, and thus may be a factor contributing to the latency of the
disease (148), (151).  This may explain why BA102 only persisted in the mouse spleen
as long as 24 weeks post-infection.  The mutation of gcvH may also cause growth
restriction of the mutant in the macrophage, despite the presence of a functional T4SS.
Such growth restriction has been observed in wild type E. coli strains harboring non-
functional selenolipoylated H-protein of the glycine cleavage system (57).  The presence
of a functional glycine cleavage system appears to be vital to the survival of Brucella in
vivo and thus is consistent with the need for additional factors for virulence.
The vaccine potential of virB10 and gcvH mutants was investigated in the
BALB/c mouse model for a period of vaccination exposure ranging from 8 weeks to 24
weeks.  As a result, the persisting gcvH mutant induced significantly high levels of
protection at 8, 16, and 24 weeks post-vaccination.  Although protection against
challenge began to decline from a maximal level observed at 16 weeks post-vaccination
for both candidates, the protection elicited by both virB10 and gcvH mutants was still
significant when compared to that of the control unvaccinated animals.  In particular, the
gcvH mutant still induced higher level of protection than the virB10 mutant.  Since the
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duration of bacterial colonization and the level of colonization of virB10 and gcvH
mutants differed, it was difficult to relate the potential differences in protection solely to
the level of colonization or the duration of colonization by the vaccine candidates
exhibiting such a wide range of in vivo persistence and bacterial burden.  Treatment with
doxycycline for 21 days followed the vaccination exposure was implemented.
To better understand the differences in protective immunity induced by these
mutants, the fundamentals of host immune responses were examined.  The host anti-
Brucella antibody, IgG, remained in circulation for an extended period even after
bacteria including those of the early-clearing virB10 mutant were cleared from the host.
A similar observation has been documented in patients clinically cured of acute
brucellosis, in which Brucella antibodies persisted for more than 2 years after successful
treatment and clinical cure (2).  The adaptive cellular immune response showed a
consistent pattern of host immune function in favor of TH1 (IgG2a>IgG1) in all
vaccinated mice except for those vaccinated with the virB10 mutant.  At 24 weeks post-
vaccination followed by 21 days of doxycycline, the IgG1 levels in animals vaccinated
with the virB10 mutant were significantly increased, suggesting that there is a
diminution of TH1 response.  A transient acquired cellular immunity has also been
observed in C3H mice upon the clearance of bacteria from tissues, despite the fact that
the C3H mouse model is more resistant to Brucella infection than the BALB/c model
(106), (155).  The BALB/c mouse model has been shown to be a TH2-driven response
model (23), (52).  Therefore, by more than 24 weeks post-inoculation, no live brucellae
of the virB10 mutant were present in the mice, the host system may have resumed its
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original state.  The induction of two TH1-associated cytokines, IFN-gamma and IL-2,
was consistent and significantly high in all Brucella-inoculated animals except for those
vaccinated with the virB10 mutant.  In these vaccinated mice, the absence of IL-2 and
the late induction of IFN-gamma observed at 24 weeks post-vaccination followed by 21-
days of doxycycline treatment may be another contributing factor that allows a favorable
change towards a TH2 characteristic.  Despite the host immune function in favor of TH1
responses, the induction of IL-10 was significantly increased in all animals including
those vaccinated with the gcvH mutant as well as those inoculated with virulent S2308.
Interleukin-10 was once clearly classified as a TH2-associated cytokine that could down-
modulate the TH1 response, and now there is mounting evidence that IL-10 may act as an
inhibitor of the TH2 response both in vivo and in vitro (157), (156).  On the contrary, our
findings suggest that IL-10 may act as an anti-inflammatory cytokine to buffer the host
systems during cellular attack, or that the effect of IL-10 in vitro does not reflect events
as they occurred one week after challenge.  In addition to cytokine profiles, results of
lymphocyte proliferation suggest that Brucella can elicit a long-term memory response
regardless of the length of persistence.  Proliferative responses were evident even in
lymphocytes from animals at 24 weeks after inoculating with the short-lived virB10
mutant.  This is somewhat surprising when considering the decline in protection
observed in response to vaccination with the mutant long after the bacteria of the virB10
mutant have cleared from the host.
Taken together, our findings suggest that the combination of enhanced levels of
TH1-type cytokines elicited by the gcvH mutant is crucial for the development and the
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maintenance of TH1 response in the host, particularly, in a Brucella-susceptible and non-
TH1-driven response host model such as the BALB/c mouse.  The strongest protection
against B. abortus not only requires a finely balance of cytokines, is more dependent
upon the timing of the cytokine response rather than on the absolute level of cytokine
expression.  Overall, the gcvH mutant conferred the greatest cellular protection against
wild type B. abortus S2308 without exerting unnecessary side effects such as
splenomegaly on the host, suggesting that greater persistence of vaccine strain correlates
with greater protection.
Persistence has always been the hallmark of chronic brucellosis as well as human
tuberculosis.  B. abortus gcvH mutant was identified within a group of attenuated STM
mutants that were unable to persist in mice.  The inactivated gene of this B. abortus
mutant was homologous to M. tuberculosis gcvB encoding glycine dehydrogenase,
which was up-regulated in a culture of tubercle bacilli during non-replicating stages.
This homology suggests that both organisms may depend on similar metabolic pathways
for chronic persistence.  A thorough sequence analysis revealed that the inactivated gene
of this B. abortus mutant is homologous not only to gcvB of M. tuberculosis but also to
gcvH of E. coli.  The homology was further defined as the genome sequence of B.
melitensis became available.  The gcvH in B. abortus, mapped to the gcv operon of B.
melitensis, is located in the middle of the gcv operon consisting of three genes in the
following order, gcvT-gcvH-gcvP.  In the B. abortus gcvH (BA102) mutant, the
transposon insertion resides in the last 40 bp of gcvH.  Thus, the disruption of the gcvH
gene may also abolish the expression of the gcvP gene.
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In an effort to restore or rescue the defect caused by the insertional mutation in
the gcvH of B. abortus, wild type copies of gcvH and/or gcvP were introduced into the
gcvH mutant, generating three complemented mutant strains. These mutant strains
showed no in vitro growth defects.  In macrophage J774A.1, the complemented mutant
strain carrying the wild type gcvH exhibited reduced intracellular survival similar to the
parental mutant strain.  In contrast, the complemented mutant strain with both wild type
gcvH and gcvP genes showed a small yet significant recovery in numbers after the initial
macrophagic killing.  Interestingly, the mutant strain harboring the wild type gcvP gene
was severely attenuated in the macrophage as the short-lived virB10 of B. abortus.
These results suggest that the expression of gcv operon may be needed for Brucella to
persist intracellularly within the macrophage and that the accumulation of the partially
processed product of the glycine cleavage system may cause a disruption of metabolic
balance in the bacterial cell.  The survival of the complemented mutant strains in mice
was also examined.  Unfortunately, bacteria of all three complemented strains were not
recoverable after a mixed infection with the parental gcvH mutant strain.  The best
explanation for this observation is the addiction module phenomenon, in which the
stability of low-copy number plasmids in the host bacterial cells is maintained by the
mechanism for killing plasmid-free bacteria provided by the addiction module.  In this
case, an addiction module may exist in pBBR1mcs vector, which was used as the
backbone of all constructs carrying B. abortus gcvH and/or gcvP, resulting in cell death
to the plasmid-free progeny upon the loss of the plasmid.  An alternative approach to
resolve the instability of the plasmid is to construct an unmarked deletional mutant
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carrying a chromosomal copy of the gene of interest, so that the complementation is the
result of gene expression from a single copy of the gene.  Thus, a suicide vector-based
construct carrying both wild type gcvH and gcvP along with a promoterless reporter
gene is introduced via a single event of homologous recombination into the chromosome
of an unmarked double (gcvH-and-gcvP) deletional mutant.  The endogeneous gcv
promoter, thus, regulates the expression of these inserted genes.  The expression level of
gcv operon can then be monitored by that of the reporter gene under in vivo or in vitro
conditions.
Virulence of Brucella is essentially the result of their capacity to survive and
replicate within the phagocytic cells.  However, many gaps remain in our understanding
of this ability of brucellae to elude the bactericidal effects of host phagocytes, and basic
questions remain unanswered.  Identification of Brucella gene products, which are
involved in the intracellular survival as well as those that contribute to the induction of
protective immunity, is critical to elucidate the molecular mechanisms of the
pathogenesis of the organism.
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